

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 March 2005 (10.03.2005)

PCT


(10) International Publication Number  
**WO 2005/021709 A2**

- (51) International Patent Classification<sup>7</sup>: C12N [US/US]; 208 Galway Bay, Alameda, CA 94502 (US). KIM, Nam [CA/US]; 1187 Doyle Circle, Santa Clara, CA 95054 (US). WOLFERT, Robert, L. [US/US]; 3582 Arbutus Avenue, Palo Alto, CA 94303 (US).
- (21) International Application Number: PCT/US2004/016969
- (22) International Filing Date: 1 June 2004 (01.06.2004) (74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrrell P.C., 66 E. Main Street, Marlton, NJ 08053 (US).
- (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (26) Publication Language: English
- (30) Priority Data:  
60/474,110 29 May 2003 (29.05.2003) US  
60/556,239 25 March 2004 (25.03.2004) US
- (71) Applicant (for US only): DIADEXUS, INC. [US/US]; 343 Oyster Point Boulevard, South San Francisco, CA 94080 (US).
- (72) Inventors; and (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
- (75) Inventors/Applicants (for US only): DUAN, Xiaozhu

[Continued on next page]

(54) Title: C1N101 ANTIBODY COMPOSITIONS AND METHODS OF USE ALONE AND IN COMBINATION WITH PROSTATE SPECIFIC ANTIGEN AND OTHER CANCER MARKERS

### Anti-C1n101 MAb Epitope Map



(57) Abstract: This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both C1n101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing C1n101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (C1n101) antibodies that bind to C1n101 in vivo. The invention also encompasses compositions comprising an anti-C1n101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-C1n101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-C1n101 antibodies. The invention encompasses a method of producing the anti-C1n101 antibodies. Other aspects of the invention are a method of killing an

C1n101 -expressing cancer cell, comprising contacting the cancer cell with an anti-C1n101 antibody and a method of alleviating or treating an C1n101 -expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-C1n101 antibody to the mammal.



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *without international search report and to be republished  
upon receipt of that report*

IP16 Rec'd PGT/PTO 29 NOV 2005

**Cln101 ANTIBODY COMPOSITIONS AND METHODS OF USE ALONE AND IN  
COMBINATION WITH PROSTATE SPECIFIC ANTIGEN AND OTHER  
CANCER MARKERS**

5 This patent application claims the benefit of priority to U.S. Provisional Patent Application Serial No. 60/ 556,239, filed March 25, 2004 and U.S. Provisional Patent Application Serial No. 60/474,110, filed May 29, 2003, each of which is incorporated by reference in its entirety.

**FIELD OF THE INVENTION**

10 The present invention relates to anti-Cln101 antibody compositions and methods for assessing risk of prostate and/or ovarian cancer. Specifically, it relates to utilizing both Cln101 (also known as Regenerating Protein IV or Reg IV) and Prostate Specific Antigen (PSA) in combination to detect prostate cancer. In addition, this invention is related to the use of Cln101 alone or in combination to detect ovarian cancer.

15 **BACKGROUND OF THE INVENTION**

Prostate Cancer

Prostate cancer is the most prevalent cancer in men and is the second leading cause of death from cancer among males in the United States. AJCC Cancer Staging Handbook 203 (Irvin D. Fleming et al. eds., 5<sup>th</sup> ed. 1998); Walter J. Burdette, Cancer: Etiology, 20 Diagnosis, and Treatment 147 (1998). In 1999, it was estimated that 37,000 men in the United States would die as result of prostate cancer. Elizabeth A. Platz et al., & Edward Giovannucci, *Epidemiology of and Risk Factors for Prostate Cancer*, in Management of Prostate Cancer 21 (Eric A Klein, ed. 2000). More recently, the American Cancer Society estimated there will be 230,110 new cases of prostate cancer and 29,900 deaths in 2004. 25 American Cancer Society website: cancer with the extension .org of the world wide web. Cancer of the prostate typically occurs in older males, with a median age of 74 years for clinical diagnosis. Burdette, *supra* at 147. A man's risk of being diagnosed with invasive prostate cancer in his lifetime is one in six. Platz et al., *supra* at 21.

Although our understanding of the etiology of prostate cancer is incomplete, the 30 results of extensive research in this area point to a combination of age, genetic and environmental/dietary factors. Platz et al., *supra* at 19; Burdette, *supra* at 147; Steven K.

Clinton, *Diet and Nutrition in Prostate Cancer Prevention and Therapy*, in Prostate Cancer: a Multidisciplinary Guide 246-269 (Philip W. Kantoff et al. eds. 1997). Broadly speaking, genetic risk factors predisposing one to prostate cancer include race and a family history of the disease. Platz et al., *supra* at 19, 28-29, 32-34. Aside from these  
5 generalities, a deeper understanding of the genetic basis of prostate cancer has remained elusive. Considerable research has been directed to studying the link between prostate cancer, androgens, and androgen regulation, as androgens play a crucial role in prostate growth and differentiation. Meena Augustus et al., *Molecular Genetics and Markers of Progression, in Management of Prostate Cancer* 59 (Eric A Klein ed. 2000). While a  
10 number of studies have concluded that prostate tumor development is linked to elevated levels of circulating androgen (e.g., testosterone and dihydrotestosterone), the genetic determinants of these levels remain unknown. Platz et al., *supra* at 29-30.

Several studies have explored a possible link between prostate cancer and the androgen receptor (AR) gene, the gene product of which mediates the molecular and  
15 cellular effects of testosterone and dihydrotestosterone in tissues responsive to androgens. *Id.* at 30. Differences in the number of certain trinucleotide repeats in exon 1, the region involved in transactivational control, have been of particular interest. Augustus et al., *supra* at 60. For example, these studies have revealed that as the number of CAG repeats decreases the transactivation ability of the gene product increases, as does the risk of  
20 prostate cancer. Platz et al., *supra* at 30-31. Other research has focused on the  $\alpha$ -reductase Type 2 gene, the gene which codes for the enzyme that converts testosterone into dihydrotestosterone. *Id.* at 30. Dihydrotestosterone has greater affinity for the AR than testosterone, resulting in increased transactivation of genes responsive to androgens. *Id.* While studies have reported differences among the races in the length of a TA  
25 dinucleotide repeat in the 3' untranslated region, no link has been established between the length of that repeat and prostate cancer. *Id.* Interestingly, while *ras* gene mutations are implicated in numerous other cancers, such mutations appear not to play a significant role in prostate cancer, at least among Caucasian males. Augustus, *supra* at 52.

Environmental/dietary risk factors which may increase the risk of prostate cancer  
30 include intake of saturated fat and calcium. Platz et al., *supra* at 19, 25-26. Conversely, intake of selenium, vitamin E and tomato products (which contain the carotenoid lycopene) apparently decrease that risk. *Id.* at 19, 26-28 The impact of physical activity,

cigarette smoking, and alcohol consumption on prostate cancer is unclear. Platz et al., *supra* at 23-25.

Periodic screening for prostate cancer is most effectively performed by digital rectal examination (DRE) of the prostate, in conjunction with determination of the serum  
5 level of prostate-specific antigen (PSA). Burdette, *supra* at 148. While the merits of such screening are the subject of considerable debate, Jerome P. Richie & Irving D. Kaplan, *Screening for Prostate Cancer: The Horns of a Dilemma*, in Prostate Cancer: A Multidisciplinary Guide 1-10 (Philip W. Kantoff et al. eds. 1997), the American Cancer Society and American Urological Association recommend that both of these tests be  
10 performed annually on men 50 years or older with a life expectancy of at least 10 years, and younger men at high risk for prostate cancer. Ian M. Thompson & John Foley, *Screening for Prostate Cancer*, in Management of Prostate Cancer 71 (Eric A Klein ed. 2000). If necessary, these screening methods may be followed by additional tests, including biopsy, ultrasonic imaging, computerized tomography, and magnetic resonance  
15 imaging. Christopher A. Haas & Martin I. Resnick, *Trends in Diagnosis, Biopsy, and Imaging*, in Management of Prostate Cancer 89-98 (Eric A Klein ed. 2000); Burdette, *supra* at 148.

Once the diagnosis of prostate cancer has been made, treatment decisions for the individual are typically linked to the stage of prostate cancer present in that individual, as  
20 well as his age and overall health. Burdette, *supra* at 151. One preferred classification system for staging prostate cancer was developed by the American Urological Association (AUA). *Id.* at 148. The AUA classification system divides prostate tumors into four broad stages, A to D, which are in turn accompanied by a number of smaller substages. Burdette, *supra* at 152-153; Anthony V. D'Amico et al., *The Staging of Prostate Cancer*,  
25 in Prostate Cancer: A Multidisciplinary Guide 41 (Philip W. Kantoff et al. eds. 1997).

Stage A prostate cancer refers to the presence of microscopic cancer within the prostate gland. D'Amico, *supra* at 41. This stage is comprised of two substages: A1, which involves less than four well-differentiated cancer foci within the prostate, and A2, which involves greater than three well-differentiated cancer foci or alternatively,  
30 moderately to poorly differentiated foci within the prostate. Burdette, *supra* at 152; D'Amico, *supra* at 41. Treatment for stage A1 preferentially involves following PSA levels and periodic DRE. Burdette, *supra* at 151. Should PSA levels rise, preferred

treatments include radical prostatectomy in patients 70 years of age and younger, external beam radiotherapy for patients between 70 and 80 years of age, and hormone therapy for those over 80 years of age. *Id.*

5       Stage B prostate cancer is characterized by the presence of a palpable lump within the prostate. Burdette, *supra* at 152-53; D'Amico, *supra* at 41. This stage is comprised of three substages: B1, in which the lump is less than 2 cm and is contained in one lobe of the prostate; B2, in which the lump is greater than 2 cm yet is still contained within one lobe; and B3, in which the lump has spread to both lobes. Burdette, *supra*, at 152-53. For stages B1 and B2, the treatment again involves radical prostatectomy in patients 70 years  
10   of age and younger, external beam radiotherapy for patients between 70 and 80 years of age, and hormone therapy for those over 80 years of age. *Id.* at 151. In stage B3, radical prostatectomy is employed if the cancer is well-differentiated and PSA levels are below 15 ng/mL; otherwise, external beam radiation is the chosen treatment option. *Id.*

15       Stage C prostate cancer involves a substantial cancer mass accompanied by extraprostatic extension. Burdette, *supra* at 153; D'Amico, *supra* at 41. Like stage A prostate cancer, Stage C is comprised of two substages: substage C1, in which the tumor is relatively minimal, with minor prostatic extension, and substage C2, in which the tumor is large and bulky, with major prostatic extension. *Id.* The treatment of choice for both substages is external beam radiation. Burdette, *supra* at 151.

20       The fourth and final stage of prostate cancer, Stage D, describes the extent to which the cancer has metastasized. Burdette, *supra* at 153; D'Amico, *supra* at 41. This stage is comprised of four substages: (1) D0, in which acid phosphatase levels are persistently high, (2) D1, in which only the pelvic lymph nodes have been invaded, (3) D2, in which the lymph nodes above the aortic bifurcation have been invaded, with or  
25   without distant metastasis, and (4) D3, in which the metastasis progresses despite intense hormonal therapy. *Id.* Treatment at this stage may involve hormonal therapy, chemotherapy, and removal of one or both testes. Burdette, *supra* at 151.

30       Despite the need for accurate staging of prostate cancer, current staging methodology is limited. The wide variety of biological behavior displayed by neoplasms of the prostate has resulted in considerable difficulty in predicting and assessing the course of prostate cancer. Augustus et al., *supra* at 47. Indeed, despite the fact that most prostate cancer patients have carcinomas that are of intermediate grade and stage, prognosis for

these types of carcinomas is highly variable. Andrew A Renshaw & Christopher L. Corless, *Prognostic Features in the Pathology of Prostate Cancer*, in Prostate Cancer: A Multidisciplinary Guide 26 (Philip W. Kantoff et al. eds. 1997). Techniques such as transrectal ultrasound, abdominal and pelvic computerized tomography, and MRI have not  
5 been particularly useful in predicting local tumor extension. D'Amico, *supra* at 53 (editors' comment). While the use of serum PSA in combination with the Gleason score is currently the most effective method of staging prostate cancer, *id.*, PSA is of limited predictive value, Augustus et al., *supra* at 47; Renshaw et al., *supra* at 26, and the Gleason score is prone to variability and error, King, C. R. & Long, J. P., *Int'l. J. Cancer* 90(6):  
10 326-30 (2000). As such, the current focus of prostate cancer research has been to obtain biomarkers to help better assess the progression of the disease. Augustus et al., *supra* at 47; Renshaw et al., *supra* at 26; Pettaway, C. A., *Tech. Urol.* 4(1): 35-42 (1998).

### Current Therapeutics

#### *Radical Prostatectomy*

15 This operation removes the entire prostate gland plus some tissue around it and is used most often if the cancer is thought not to have spread outside of the gland. There are two main types of radical prostatectomy: radical retropubic prostatectomy and radical perineal prostatectomy. In the retropubic operation, the surgeon makes a skin incision in the lower abdomen. The surgeon can remove lymph nodes during this operation through  
20 the same incision. A nerve-sparing radical retropubic prostatectomy is a modification of this operation.

The radical peritoneal prostatectomy removes the prostate through an incision in the skin between the scrotum and anus. Nerve-sparing operations are more difficult by this approach and lymph nodes cannot be removed through this incision. If lymph node  
25 examination is needed for men having a radical peritoneal prostatectomy, the surgeon can remove some lymph nodes through a very small skin incision in the abdomen or by using a laparoscope. A laparoscope is a long slender tube through which a surgeon can view and remove lymph nodes near the prostate gland.

#### *Radiation Therapy*

30 Radiation is sometimes used to treat prostate cancer that is still confined to the prostate gland, or has spread to nearby tissue. If the disease is more advanced, radiation

may be used to reduce the size of the tumor. The two main types of radiation therapy are external beam radiation and brachytherapy (internal radiation) and internal radiation therapy (brachytherapy). Internal radiation therapy uses small radioactive pellets (each about the size of a grain of rice) that are directly implanted (permanently or temporarily) into the prostate.

### *Hormone Therapy*

This treatment is often used for patients whose prostate cancer has spread beyond the prostate or has recurred after treatment. The goal of hormone therapy is to lower levels of the male hormones, androgens. The main androgen is called testosterone. Androgens are produced mainly in the testicles and cause prostate cancer cells to grow. Lowering androgen levels can make prostate cancers shrink or grow more slowly. But, hormone therapy does not cure the cancer. There are several methods used for hormone therapy.

Some prostate cancers do not respond to hormone therapy, and are called androgen independent cancers. Some prostate cancers respond to hormonal therapy for a few years before becoming androgen independent. Less often, prostate cancers may be androgen independent at the time they are diagnosed.

Orchiectomy: This operation removes the testicles. Although it is a surgical treatment, orchiectomy is considered hormonal therapy because it works by removing the main source of male hormones.

Luteinizing hormone-releasing hormone (LHRH) analogs: These drugs can decrease the amount of testosterone produced by a man's testicles, as effectively as surgical removal of the testicles. LHRH analogs (also called LHRH agonists) are injected either monthly or every three months. The two LHRH analogs currently available in the United States are leuprolide (Lupron®) and goserelin (Zoladex®).

Anti-androgens: Even after orchiectomy or during treatment with LHRH analogs, a small amount of androgen is still produced by the adrenal glands. Anti-androgens block the body's ability to use androgens. Drugs of this type, such as flutamide (Eulexin®), bicalutamide (Casodex®), and nilutamide (Nilandron®), are taken as pills, once or three times a day. Anti-androgens are often used in combination with orchiectomy or LHRH analogs. This combination is called total androgen blockade.

Other hormonal drugs: Megestrol acetate (Megace®) and medroxyprogesterone (Depo-Provera®) are sometimes used if "first-line" hormonal treatments lose

effectiveness. Ketoconazole (Nizoral®), initially used for treating fungal infections and later found to also work as an anti-androgen, is another drug for "second line" hormonal therapy.

### *Chemotherapy*

5        Chemotherapy is an option for patients whose prostate cancer has spread outside of the prostate gland and for whom hormone therapy has failed. It is not expected to destroy all of the cancer cells, but it may slow tumor growth and reduce pain.

Some of the chemotherapy drugs used in treating prostate cancer that has returned or continued to grow and spread after treatment with hormonal therapy include  
10    doxorubicin (Adriamycin), estramustine, etoposide, mitoxantrone, vinblastine, and paclitaxel. Two or more drugs are often given together to reduce the likelihood of the cancer cells becoming resistant to chemotherapy. Small cell carcinoma is a rare type of prostate cancer that is more likely to respond to chemotherapy than to hormonal therapy. Small cell carcinoma develops more often in the lungs than in the prostate. Since small  
15    cell lung cancer often responds to chemotherapy with cisplatin and etoposide, these drugs are recommended for treating small cell cancers that develop in the prostate.

Accordingly, there is a great need for more sensitive and accurate methods for predicting whether a person is likely to develop prostate cancer, for diagnosing prostate cancer, for monitoring the progression of the disease, for staging the prostate cancer, for  
20    determining whether the prostate cancer has metastasized and for imaging the prostate cancer. There is also a need for better treatment of prostate cancer.

### Ovarian Cancer

Cancer of the ovaries is the fourth-most common cause of cancer death in women in the United States, with more than 23,000 new cases and roughly 14,000 deaths  
25    predicted for the year 2001. Shridhar, V. et al., *Cancer Res.* 61(15): 5895-904 (2001); Memarzadeh, S. & Berek, J. S., *J. Reprod. Med.* 46(7): 621-29 (2001). The American Cancer Society estimates that there will be about 25,580 new cases of ovarian cancer in 2004 in the United States alone. Ovarian cancer will cause about 16,090 deaths in the United States in the same year. ACS Website: cancer with the extension .org of the world  
30    wide web. The incidence of ovarian cancer is of serious concern worldwide, with an estimated 191,000 new cases predicted annually. Runnebaum, I. B. & Stickeler, E., *J. Cancer Res. Clin. Oncol.* 127(2): 73-79 (2001). Unfortunately, women with ovarian

cancer are typically asymptomatic until the disease has metastasized. Because effective screening for ovarian cancer is not available, roughly 70% of women diagnosed have an advanced stage of the cancer with a five-year survival rate of ~25-30%. Memarzadeh, S. & Berek, J. S., *supra*; Nunns, D. et al., *Obstet. Gynecol. Surv.* 55(12): 746-51. Conversely, women diagnosed with early stage ovarian cancer enjoy considerably higher survival rates. Werness, B. A. & Eltabbakh, G. H., *Int'l. J. Gynecol. Pathol.* 20(1): 48-63 (2001). Although our understanding of the etiology of ovarian cancer is incomplete, the results of extensive research in this area point to a combination of age, genetics, reproductive, and dietary/environmental factors. Age is a key risk factor in the development of ovarian cancer: while the risk for developing ovarian cancer before the age of 30 is slim, the incidence of ovarian cancer rises linearly between ages 30 to 50, increasing at a slower rate thereafter, with the highest incidence being among septagenarian women. Jeanne M. Schilder et al., *Hereditary Ovarian Cancer: Clinical Syndromes and Management*, in Ovarian Cancer 182 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001).

With respect to genetic factors, a family history of ovarian cancer is the most significant risk factor in the development of the disease, with that risk depending on the number of affected family members, the degree of their relationship to the woman, and which particular first degree relatives are affected by the disease. *Id.* Mutations in several genes have been associated with ovarian cancer, including BRCA1 and BRCA2, both of which play a key role in the development of breast cancer, as well as hMSH2 and hMLH1, both of which are associated with hereditary non-polyposis colon cancer. Katherine Y. Look, *Epidemiology, Etiology, and Screening of Ovarian Cancer*, in Ovarian Cancer 169, 171-73 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). BRCA1, located on chromosome 17, and BRCA2, located on chromosome 13, are tumor suppressor genes implicated in DNA repair; mutations in these genes are linked to roughly 10% of ovarian cancers. *Id.* at 171-72; Schilder et al., *supra* at 185-86. hMSH2 and hMLH1 are associated with DNA mismatch repair, and are located on chromosomes 2 and 3, respectively; it has been reported that roughly 3% of hereditary ovarian carcinomas are due to mutations in these genes. Look, *supra* at 173; Schilder et al., *supra* at 184, 188-89.

Reproductive factors have also been associated with an increased or reduced risk of ovarian cancer. Late menopause, nulliparity, and early age at menarche have all been linked with an elevated risk of ovarian cancer. Schilder et al., *supra* at 182. One theory

hypothesizes that these factors increase the number of ovulatory cycles over the course of a woman's life, leading to "incessant ovulation," which is thought to be the primary cause of mutations to the ovarian epithelium. *Id.*; Laura J. Havrilesky & Andrew Berchuck, *Molecular Alterations in Sporadic Ovarian Cancer*, in Ovarian Cancer 25 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). The mutations may be explained by the fact that ovulation results in the destruction and repair of that epithelium, necessitating increased cell division, thereby increasing the possibility that an undetected mutation will occur. *Id.* Support for this theory may be found in the fact pregnancy, lactation, and the use of oral contraceptives, all of which suppress ovulation, confer a protective effect with respect to developing ovarian cancer. *Id.*

Among dietary/environmental factors, there would appear to be an association between high intake of animal fat or red meat and ovarian cancer, while the antioxidant Vitamin A, which prevents free radical formation and also assists in maintaining normal cellular differentiation, may offer a protective effect. Look, *supra* at 169. Reports have also associated asbestos and hydrous magnesium trisilicate (talc), the latter of which may be present in diaphragms and sanitary napkins. *Id.* at 169-70.

Current screening procedures for ovarian cancer, while of some utility, are quite limited in their diagnostic ability, a problem that is particularly acute at early stages of cancer progression when the disease is typically asymptomatic yet is most readily treated. Walter J. Burdette, *Cancer: Etiology, Diagnosis, and Treatment* 166 (1998); Memarzadeh & Berek, *supra*; Runnebaum & Stickeler, *supra*; Werness & Eltabbakh, *supra*. Commonly used screening tests include biannual rectovaginal pelvic examination, radioimmunoassay to detect the CA-125 serum tumor marker, and transvaginal ultrasonography. Burdette, *supra* at 166.

Pelvic examination has failed to yield adequate numbers of early diagnoses, and the other methods are not sufficiently accurate. *Id.* One study reported that only 15% of patients who suffered from ovarian cancer were diagnosed with the disease at the time of their pelvic examination. Look, *supra* at 174. Moreover, the CA-125 test is prone to giving false positives in pre-menopausal women and has been reported to be of low predictive value in post-menopausal women. *Id.* at 174-75. Although transvaginal ultrasonography is now the preferred procedure for screening for ovarian cancer, it is unable to distinguish reliably between benign and malignant tumors, and also cannot

locate primary peritoneal malignancies or ovarian cancer if the ovary size is normal. Schilder et al., *supra* at 194-95. While genetic testing for mutations of the BRCA1, BRCA2, hMSH2, and hMLH1 genes is now available, these tests may be too costly for some patients and may also yield false negative or indeterminate results. Schilder et al.,  
5 *supra* at 191-94.

Other markers of interest are HE4 and mesothelin, see Urban et al. Ovarian cancer screening Hematol Oncol Clin North Am. 2003 Aug;17(4):989-1005; Hellstrom et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Res. 2003 Jul 1;63(13):3695-700; Ordonez, Application of mesothelin immunostaining in tumor  
10 diagnosis, Am J Surg Pathol. 2003 Nov;27(11):1418-28.

The staging of ovarian cancer, which is accomplished through surgical exploration, is crucial in determining the course of treatment and management of the disease. AJCC Cancer Staging Handbook 187 (Irvin D. Fleming et al. eds., 5th ed. 1998); Burdette, *supra* at 170; Memarzadeh & Berek, *supra*; Shridhar et al., *supra*. Staging is performed  
15 by reference to the classification system developed by the International Federation of Gynecology and Obstetrics. David H. Moore, *Primary Surgical Management of Early Epithelial Ovarian Carcinoma*, in Ovarian Cancer 203 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001); Fleming et al. eds., *supra* at 188. Stage I ovarian cancer is characterized by tumor growth that is limited to the ovaries and is comprised of three  
20 substages. *Id.* In substage IA, tumor growth is limited to one ovary, there is no tumor on the external surface of the ovary, the ovarian capsule is intact, and no malignant cells are present in ascites or peritoneal washings. *Id.* Substage IB is identical to A1, except that tumor growth is limited to both ovaries. *Id.* Substage IC refers to the presence of tumor growth limited to one or both ovaries, and also includes one or more of the following  
25 characteristics: capsule rupture, tumor growth on the surface of one or both ovaries, and malignant cells present in ascites or peritoneal washings. *Id.*

Stage II ovarian cancer refers to tumor growth involving one or both ovaries, along with pelvic extension. *Id.* Substage IIA involves extension and/or implants on the uterus and/or fallopian tubes, with no malignant cells in the ascites or peritoneal washings, while  
30 substage IIB involves extension into other pelvic organs and tissues, again with no malignant cells in the ascites or peritoneal washings. *Id.* Substage IIC involves pelvic

extension as in IIA or IIB, but with malignant cells in the ascites or peritoneal washings.  
*Id.*

Stage III ovarian cancer involves tumor growth in one or both ovaries, with peritoneal metastasis beyond the pelvis confirmed by microscope and/or metastasis in the regional lymph nodes. *Id.* Substage IIIA is characterized by microscopic peritoneal metastasis outside the pelvis, with substage IIIB involving macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension. *Id.* Substage IIIC is identical to IIIB, except that the metastasis is greater than 2 cm in greatest dimension and may include regional lymph node metastasis. *Id.* Lastly, Stage IV refers to the presence distant metastasis, excluding peritoneal metastasis. *Id.*

While surgical staging is currently the benchmark for assessing the management and treatment of ovarian cancer, it suffers from considerable drawbacks, including the invasiveness of the procedure, the potential for complications, as well as the potential for inaccuracy. Moore, *supra* at 206-208, 213. In view of these limitations, attention has turned to developing alternative staging methodologies through understanding differential gene expression in various stages of ovarian cancer and by obtaining various biomarkers to help better assess the progression of the disease. Vartiainen, J. et al., *Int'l J. Cancer*, 95(5): 313-16 (2001); Shridhar et al. *supra*; Baekelandt, M. et al., *J. Clin. Oncol.* 18(22): 3775-81.

The treatment of ovarian cancer typically involves a multiprong attack, with surgical intervention serving as the foundation of treatment. Dennis S. Chi & William J. Hoskins, *Primary Surgical Management of Advanced Epithelial Ovarian Cancer*, in *Ovarian Cancer* 241 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). For example, in the case of epithelial ovarian cancer, which accounts for ~90% of cases of ovarian cancer, treatment typically consists of: (1) cytoreductive surgery, including total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy, followed by (2) adjuvant chemotherapy with paclitaxel and either cisplatin or carboplatin. Eltabbakh, G.H. & Awtrey, C.S., *Expert Op. Pharmacother.* 2(10): 109-24. Despite a clinical response rate of 80% to the adjuvant therapy, most patients experience tumor recurrence within three years of treatment. *Id.* Certain patients may undergo a second cytoreductive surgery and/or second-line chemotherapy. Memarzadeh & Berek, *supra*.

From the foregoing, it is clear that procedures used for detecting, diagnosing, monitoring, staging, prognosticating, and preventing the recurrence of ovarian cancer are of critical importance to the outcome of the patient. Moreover, current procedures, while helpful in each of these analyses, are limited by their specificity, sensitivity, invasiveness, and/or their cost. As such, highly specific and sensitive procedures that would operate by way of detecting novel markers in cells, tissues, or bodily fluids, with minimal invasiveness and at a reasonable cost, would be highly desirable.

Accordingly, there is a great need for more sensitive and accurate methods for predicting whether a person is likely to develop ovarian cancer, for diagnosing ovarian cancer, for monitoring the progression of the disease, for staging the ovarian cancer, for determining whether the ovarian cancer has metastasized, for imaging the ovarian cancer and for better treatment of ovarian cancer.

#### Angiogenesis in Cancer

Growth and metastasis of solid tumors are also dependent on angiogenesis.

Folkman, J., 1986, *Cancer Research*, 46, 467-473; Folkman, J., 1989, *Journal of the National Cancer Institute*, 82, 4-6. It has been shown, for example, that tumors which enlarge to greater than 2 mm must obtain their own blood supply and do so by inducing the growth of new capillary blood vessels. Once these new blood vessels become embedded in the tumor, they provide a means for tumor cells to enter the circulation and metastasize to distant sites such as liver, lung or bone. Weidner, N., *et al.*, 1991, *The New England Journal of Medicine*, 324(1), 1-8.

Angiogenesis, defined as the growth or sprouting of new blood vessels from existing vessels, is a complex process that primarily occurs during embryonic development. The process is distinct from vasculogenesis, in that the new endothelial cells lining the vessel arise from proliferation of existing cells, rather than differentiating from stem cells. The process is invasive and dependent upon proteolysis of the extracellular matrix (ECM), migration of new endothelial cells, and synthesis of new matrix components. Angiogenesis occurs during embryogenic development of the circulatory system; however, in adult humans, angiogenesis only occurs as a response to a pathological condition (except during the reproductive cycle in women).

Under normal physiological conditions in adults, angiogenesis takes place only in very restricted situations such as hair growth and wounding healing. Auerbach, W. and

Auerbach, R., 1994, *Pharmacol Ther.* 63(3):265-311; Ribatti et al., 1991, *Haematologica* 76(4):311-20; Risau, 1997, *Nature* 386(6626):671-4. Angiogenesis progresses by a stimulus which results in the formation of a migrating column of endothelial cells.

Proteolytic activity is focused at the advancing tip of this "vascular sprout", which breaks  
5 down the ECM sufficiently to permit the column of cells to infiltrate and migrate. Behind the advancing front, the endothelial cells differentiate and begin to adhere to each other, thus forming a new basement membrane. The cells then cease proliferation and finally define a lumen for the new arteriole or capillary.

Unregulated angiogenesis has gradually been recognized to be responsible for a  
10 wide range of disorders, including, but not limited to, cancer, cardiovascular disease, rheumatoid arthritis, psoriasis and diabetic retinopathy. Folkman, 1995, *Nat Med* 1(1):27-31; Isner, 1999, *Circulation* 99(13):1653-5; Koch, 1998, *Arthritis Rheum* 41(6):951-62; Walsh, 1999, *Rheumatology* (Oxford) 38(2):103-12; Ware and Simons, 1997, *Nat Med* 3(2):158-64.

Of particular interest is the observation that angiogenesis is required by solid  
15 tumors for their growth and metastases. Folkman, 1986 *supra*; Folkman 1990, *J Natl. Cancer Inst.*, 82(1) 4-6; Folkman, 1992, *Semin Cancer Biol* 3(2):65-71; Zetter, 1998, *Annu Rev Med* 49:407-24. A tumor usually begins as a single aberrant cell which can proliferate only to a size of a few cubic millimeters due to the distance from available capillary beds,  
20 and it can stay 'dormant' without further growth and dissemination for a long period of time. Some tumor cells then switch to the angiogenic phenotype to activate endothelial cells, which proliferate and mature into new capillary blood vessels. These newly formed blood vessels not only allow for continued growth of the primary tumor, but also for the dissemination and recolonization of metastatic tumor cells. The precise mechanisms that  
25 control the angiogenic switch is not well understood, but it is believed that neovascularization of tumor mass results from the net balance of a multitude of angiogenesis stimulators and inhibitors Folkman, 1995, *supra*.

One of the most potent angiogenesis inhibitors is endostatin identified by O'Reilly and Folkman. O'Reilly et al., 1997, *Cell* 88(2):277-85; O'Reilly et al., 1994, *Cell* 79(2):3  
30 15-28. Its discovery was based on the phenomenon that certain primary tumors can inhibit the growth of distant metastases. O'Reilly and Folkman hypothesized that a primary tumor initiates angiogenesis by generating angiogenic stimulators in excess of inhibitors.

However, angiogenic inhibitors, by virtue of their longer half life in the circulation, reach the site of a secondary tumor in excess of the stimulators. The net result is the growth of primary tumor and inhibition of secondary tumor. Endostatin is one of a growing list of such angiogenesis inhibitors produced by primary tumors. It is a proteolytic fragment of a larger protein: endostatin is a 20 kDa fragment of collagen XVIII (amino acid H1132-K1315 in murine collagen XVIII). Endostatin has been shown to specifically inhibit endothelial cell proliferation in vitro and block angiogenesis in vivo. More importantly, administration of endostatin to tumor-bearing mice leads to significant tumor regression, and no toxicity or drug resistance has been observed even after multiple treatment cycles.

Boehm et al., 1997, Nature 390(6658):404-407. The fact that endostatin targets genetically stable endothelial cells and inhibits a variety of solid tumors makes it a very attractive candidate for anticancer therapy. Fidler and Ellis, 1994, Cell 79(2):185-8; Gastl et al., 1997, Oncology 54(3):177-84; Hinsbergh et al., 1999, Ann Oncol 10 Suppl 4:60-3. In addition, angiogenesis inhibitors have been shown to be more effective when combined with radiation and chemotherapeutic agents. Klement, 2000, J. Clin Invest, 105(8) R15-24. Browder, 2000, Cancer Res. 6-(7) 1878-86, Arap et al., 1998, Science 279(5349):377-80; Mauceri et al., 1998, Nature 394(6690):287-91.

The present invention provides alternative methods of detecting prostate and ovarian cancer that overcome the limitations of conventional diagnostic methods as well as offer additional advantages that will be apparent from the detailed description below. Furthermore, the present invention provides alternative methods of treating prostate and ovarian cancer that overcome the limitations of conventional therapeutic methods as well as offer additional advantages that will be apparent from the detailed description below.

#### SUMMARY OF THE INVENTION

This invention is directed to a method for assessing risk of prostate cancer in a patient which comprises measuring levels of both Cln101 and Prostate Specific Antigen (PSA) in the patient, analyzing a risk associated with the level of PSA and a risk associated with the level of Cln101, and using the combined risks to assess the risk of prostate Cancer in the patient. In one aspect of the invention the measuring of PSA and Cln101 levels are done simultaneously. In another aspect of the invention the measuring of PSA and Cln101 are done sequentially.

In yet another aspect of the invention, the respective levels of PSA and Cln101 are based on dividing a patient population dataset into borderline levels of PSA and elevated levels of Cln101 and a patient having both borderline PSA and high Cln101 levels is indicative of heightened risk of prostate cancer. The borderline levels of PSA may be  
5 between about 2 ng/mL and about 10 ng/mL. The borderline levels of PSA may also between about 4 ng/mL and about 10 ng/mL or between about 2 ng/mL and about 4 ng/mL.

In addition, the invention is directed to a method of detecting ovarian cancer.

The invention is also directed to a method for treating a subject with elevated risk  
10 of a prostate cancer, comprising: selecting a subject who has borderline levels of Prostate Specific Antigen (PSA) and elevated levels of Cln101 and treating the subject with a therapy selected from the group consisting of surgery, radiation therapy, hormone therapy or chemotherapy so as to alleviate the elevated risk of prostate cancer in the subject. The invention is also directed to a method for treating a subject with elevated risk of a Prostate  
15 Cancer, comprising: selecting a subject who has borderline levels of Prostate Specific Antigen (PSA) and elevated levels of Cln101 and treating the subject with a therapy selected from the group consisting of surgery, radiation therapy, hormone therapy or chemotherapy so as to alleviate the elevated risk of prostate cancer in the subject.

Lastly the invention is directed to a kit for diagnosing a patient's susceptibility to  
20 prostate cancer comprising both a suitable assay for measuring Cln101 levels and a suitable assay for measuring Prostate Specific Antigen (PSA) levels wherein the levels of both PSA and Cln101 are determined.

This invention is directed to an isolated Cln101 antibody that binds to Cln101 on a mammalian cell in vivo. The invention is further directed to an isolated Cln101 antibody  
25 that internalizes upon binding to Cln101 on a mammalian cell in vivo. The antibody may be a monoclonal antibody. Alternatively, the antibody is an antibody fragment or a chimeric or a humanized antibody. The monoclonal antibody may be produced by a hybridoma selected from the group of hybridomas deposited under American Type Culture Collection accession number PTA-5877 and PTA-5876.

30 The antibody may compete for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma selected from the group of hybridomas

deposited under the American Type Culture Collection accession number PTA-5877 and PTA-5876.

The invention is also directed to conjugated antibodies. They may be conjugated to a growth inhibitory agent or a cytotoxic agent. The cytotoxic agent may be selected  
5 from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes and toxins. Examples of toxins include, but are not limited to, maytansin, maytansinoids, saporin, gelonin, ricin or calicheamicin.

The mammalian cell may be a cancer cell. Preferably, the anti-Cln101 monoclonal antibody that inhibits the growth of Cln101-expressing cancer cells in vivo.

10 The antibody may be produced in bacteria. Alternatively, the antibody may be a humanized form of an anti-Cln101 antibody produced by a hybridoma selected from the group of hybridomas having ATCC accession number PTA-5877 and PTA-5876.

Preferably, the cancer is selected from the group consisting of prostate and ovarian cancer. The invention is also directed to a method of producing the antibodies comprising  
15 culturing an appropriate cell and recovering the antibody from the cell culture.

The invention is also directed to compositions comprising the antibodies and a carrier. The antibody may be conjugated to a cytotoxic agent. The cytotoxic agent may be a radioactive isotope or other chemotherapeutic agent.

The invention is also directed to a method of killing a Cln101-expressing cancer  
20 cell, comprising contacting the cancer cell with the antibodies of this invention, thereby killing the cancer cell. The cancer cell may be selected from the group consisting of prostate and ovarian cancer cell.

The prostate or ovarian cancer may be ovarian serous adenocarcinoma or metastatic cancer.

25 The invention is also directed to a method of alleviating a Cln101-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the antibodies to the mammal.

In addition, the invention is directed to an article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an  
30 antibody as described herein. The article of manufacture may also comprise an additional component, e.g., a package insert indicating that the composition can be used to treat prostate or ovarian cancer.

## BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1 shows the Anti-Cln101 MAb Epitope Map.

FIGURE 2 shows Detection of Cln101 in Normal and Cancer Serum Samples (primary panel).

5 FIGURE 3 shows Detection of Cln101 in Normal and Cancer Serum Samples (primary panel), Expanded Scale.

FIGURE 4 shows Detection of Cln101 in Normal and Cancer Serum Samples (multiple panels).

10 FIGURE 5 shows Detection of Cln101 in Normal and Cancer Serum Samples (multiple panels), Expanded Scale.

FIGURE 6 shows Detection of Cln101 in Normal and Cancer Serum Samples (master panel).

FIGURE 7 shows Detection of Cln101 in Normal and Cancer Serum Samples (master panel), Expanded Scale.

15 FIGURE 8 shows Detection of Cln101 in Normal, Prostate Cancer and Prostate Benign Serum Samples.

FIGURE 9 shows Detection of PSA in Normal, Prostate Cancer and Prostate Benign Serum Samples.

20 FIGURE 10 shows Detection of Cln101 in Normal, Ovarian Cancer and Ovarian Benign Serum Samples

FIGURE 11 shows ROC Curves for Cln101 and PSA in Prostate Cancer vs. Normal Serum Samples.

FIGURE 12 shows ROC Curves for Cln101 and PSA in Prostate Cancer and Benign Disease vs. Normal Serum Samples.

25 DETAILED DESCRIPTION OF THE INVENTION

Definitions and General Techniques

Human "Cln101" as used herein, refers to a protein of 158 amino acids that is secreted from cells. The nucleotide and amino acid sequences of Cln101 have been disclosed, e.g., WO200020640-A1, DIADEXUS, Human cancer specific protein, CC-2;  
30 WO9639541-A1 HUMAN GENOME SCIENCES, Human colon specific protein; and

J.C. Hartupée *et al.* Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: Reg IV. *Biochim Biophys Acta*. 2001 Apr 16;1518(3):287-93. Most of the amino acids of Cln101 are understood to be secreted from cells. Cln101 has also been disclosed in the REFSEQ database as: NM\_032044.2 (GI: 36054181) Homo sapiens regenerating islet-derived family, member 4 (REG4, REG IV). Cln101 (REG IV) protein contains N-terminal signal peptide and the following domains: C-type lectin domain (InterPro Accession: IPR001304) and Pancreatitis-associated domain (InterPro Accession: IPR003990). The InterPro database is accessible at the European Bioinformatics Institute (EBI) website, ebi with the extension .ac.uk of the world wide web, the contents of which are incorporated by reference.

Cln101 as used herein include allelic variants and conservative substitution mutants of the protein which have Cln101 biological activity.

Recently, a series of independent publications have linked Cln101 to colorectal and gastric cancer. See Violette, S. *et al.* Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. *Int. J. Cancer* 103:185-193 (2003); Kamarainen, M. *et al.* RELP, a novel human REG-like protein with up-regulated expression in inflammatory and metaplastic gastrointestinal mucosa. *Am. J. Pathol.* 163:11-20 (2003); Yonemura, Y. *et al.* REG gene expression is associated with the infiltrating growth of gastric carcinoma. *Cancer* 98:1394-1400 (2003); Zhang, Y. *et al.* Overexpression of Reg IV in colorectal adenoma. *Cancer Lett.* 200:69-76 (2003).

Our findings that Cln101 is apparently associated to prostate and ovarian cancers make this antigen an attractive target for detection and immunotherapy of these and possibly other tumor types.

The term "antibody" (Ab) as used herein includes monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity. The term "immunoglobulin" (Ig) is used interchangeably with "antibody" herein.

An "isolated antibody" is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. Preferably, the antibody will be purified (1) to greater than 95%

by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

The basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains (an IgM antibody consists of 5 of the basic heterotetramer unit along with an additional polypeptide called J chain, and therefore contain 10 antigen binding sites, while secreted IgA antibodies can polymerize to form polyvalent assemblages comprising 2-5 of the basic 4-chain units along with J chain). In the case of IgGs, the 4-chain unit is generally about 150,000 daltons. Each L chain is linked to an H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has at the N-terminus, a variable domain (VH) followed by three constant domains (CH) for each of the  $\alpha$ ,  $\delta$  and  $\gamma$  chains and four CH domains for  $\mu$  and  $\epsilon$  isotypes. Each L chain has at the N-terminus, a variable domain (VL) followed by a constant domain (CL) at its other end.

The VL is aligned with the VH and the CL is aligned with the first constant domain of the heavy chain (CH1). Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains. The pairing of a VH and VL together forms a single antigen-binding site. For the structure and properties of the different classes of antibodies, see, e.g., Basic and Clinical Immunology, 8th edition, Daniel P. Stites, Abba I. Teff and Tristram G. Parslow (eds.), Appleton & Lange, Norwalk, CT, 1994, page 71 and Chapter 6.

The L chain from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains (CH), immunoglobulins can be assigned to different classes or isotypes.

There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, having heavy chains designated  $\alpha$ ,  $\delta$ ,  $\epsilon$ ,  $\gamma$  and  $\mu$ , respectively. The  $\gamma$  and  $\alpha$  classes are further divided into subclasses on the basis of relatively minor differences in  $C_H$  sequence and function, e.g., humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

5       The term "variable" refers to the fact that certain segments of the variable domains differ extensively in sequence among antibodies. The V domain mediates antigen binding and define specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed across the 1-10-amino acid span of the variable domains. Instead, the V regions consist of relatively invariant stretches called framework  
10 regions (FRs) of 15-30 amino acids separated by shorter regions of extreme variability called "hypervariable regions" that are each 9-12 amino acids long. The variable domains of native heavy and light chains each comprise four FRs, largely adopting a P-sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the P-sheet structure. The hypervariable regions in each  
15 chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector  
20 functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).

The term "hypervariable region" when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region generally comprises amino acid residues from a "complementarity determining  
25 region" or "CDR" (e.g. around about residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the VL, and around about 1-35 (H1), 50-65 (H2) and 95-102 (H3) in the VH; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (e.g. residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the VL, and 26-32 (H1), 53-55  
30 (1-12) and 96-101 (H3) in the VH; Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies

comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies useful in the present invention may be prepared by the hybridoma methodology first described by Kohler et al., *Nature*, 256:495 (1975), or may be made using recombinant DNA methods in bacterial, eukaryotic animal or plant cells (see, e.g., U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al., *Nature*, 352:624-628 (1991) and Marks et al., *J. Mol. Biol.*, 222:581-597 (1991), for example.

The monoclonal antibodies herein include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see U.S. Patent No. 4,816,567; and Morrison et al., *Proc. Natl. Acad. Sci. USA*, 81:6851-6855 (1984)). Chimeric antibodies of interest herein include "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey, Ape etc), and human constant region sequences.

An "intact" antibody is one which comprises an antigen-binding site as well as a CL and at least heavy chain constant domains, CH1, CH2 and CH3. The constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid sequence variant thereof. Preferably, the intact antibody has one or more effector functions.

An "antibody fragment" comprises a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies (see US patent 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain  
5 antibody molecules; and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of an entire L chain along with the variable region domain of the H chain (VH), and the first constant domain of one heavy chain (CH1). Each  
10 Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of an antibody yields a single large F(ab')<sub>2</sub> fragment which roughly corresponds to two disulfide linked Fab fragments having divalent antigen-binding activity and is still capable of cross-linking antigen. Fab' fragments differ from Fab fragments by having additional few residues at the carboxy terminus of the CH1  
15 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')<sub>2</sub> antibody fragments originally were produced as pairs of 8 Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

20 The Fc fragment comprises the carboxy-terminal portions of both H chains held together by disulfides. The effector functions of antibodies are determined by sequences in the Fc region, which region is also the part recognized by Fc receptors (FcR) found on certain types of cells.

"Fv" is the minimum antibody fragment which contains a complete antigen-  
25 recognition and -binding site. This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv  
30 comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

"Single-chain Fv" also abbreviated as "sFv" or "scFv" are antibody fragments that comprise the VH and VL antibody domains connected into a single polypeptide chain. Preferably, the sFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the sFv to form the desired structure for antigen binding.

5 For a review of sFv, see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); Borrebaeck 1995, *infra*.

The term "diabodies" refers to small antibody fragments prepared by constructing sFv fragments (see preceding paragraph) with short linkers (about 5-10 residues) between  
10 the VH and VL domains such that inter-chain but not intra-chain pairing of the V domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen-binding sites. Bispecific diabodies are heterodimers of two "crossover" sFv fragments in which the VH and VL domains of the two antibodies are present on different polypeptide chains. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and  
15 Hollinger et al., *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993).

A "native sequence" polypeptide is one which has the same amino acid sequence as a polypeptide (e.g., antibody) derived from nature. Such native sequence polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. Thus, a native sequence polypeptide can have the amino acid sequence of a naturally occurring  
20 human polypeptide, murine polypeptide, or polypeptide from any other mammalian species.

The term "amino acid sequence variant" refers to a polypeptide that has amino acid sequences that differ to some extent from a native sequence polypeptide. Ordinarily, amino acid sequence variants of Cln101 will possess at least about 70% homology with  
25 the native sequence Cln101, preferably, at least about 80%, more preferably at least about 85%, even more preferably at least about 90% homology, and most preferably at least 95%. The amino acid sequence variants can possess substitutions, deletions, and/or insertions at certain positions within the amino acid sequence of the native amino acid sequence.

30 The phrase "functional fragment or analog" of an antibody is a compound having qualitative biological activity in common with a full-length antibody. For example, a functional fragment or analog of an anti-IgE antibody is one which can bind to an IgE

immunoglobulin in such a manner so as to prevent or substantially reduce the ability of such molecule from having the ability to bind to the high affinity receptor, FcεRI.

"Homology" is defined as the percentage of residues in the amino acid sequence variant that are identical after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Methods and computer programs for the alignment are well known in the art. Sequence similarity may be measured by any common sequence analysis algorithm, such as GAP or BESTFIT or other variation Smith-Waterman alignment. See, T. F. Smith and M. S. Waterman, J. Mol. Biol. 147:195-197 (1981) and W.R. Pearson, Genomics 11:635-650 (1991).

"Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired antibody specificity, affinity, and capability. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).

As used herein, an anti-Cln101 antibody that "internalizes" is one that is taken up by (i.e., enters) the cell upon binding to Cln101 on a mammalian cell (i.e. cell surface Cln101). The internalizing antibody will of course include antibody fragments, human or humanized antibody and antibody conjugate. For therapeutic applications, internalization in vivo is contemplated. The number of antibody molecules internalized will be sufficient

or adequate to kill a Cln101-expressing cell, especially a Cln101-expressing cancer cell. Depending on the potency of the antibody or antibody conjugate, in some instances, the uptake of a single antibody molecule into the cell is sufficient to kill the target cell to which the antibody binds. For example, certain toxins are highly potent in killing such that internalization of one molecule of the toxin conjugated to the antibody is sufficient to kill the tumor cell.

Whether an anti-Cln101 antibody internalizes upon binding Cln101 on a mammalian cell can be determined by various assays including those described in the experimental examples below. For example, to test internalization in vivo, the test antibody is labeled and introduced into an animal known to have Cln101 expressed on the surface of certain cells. The antibody can be radiolabeled or labeled with fluorescent or gold particles, for instance. Animals suitable for this assay include a mammal such as a NCR nude mouse that contains a human Cln101-expressing tumor transplant or xenograft, or a mouse into which cells transfected with human Cln101 have been introduced, or a transgenic mouse expressing the human Cln101 transgene. Appropriate controls include animals that did not receive the test antibody or that received an unrelated antibody, and animals that received an antibody to another antigen on the cells of interest, which antibody is known to be internalized upon binding to the antigen. The antibody can be administered to the animal, e.g., by intravenous injection. At suitable time intervals, tissue sections of the animal can be prepared using known methods or as described in the experimental examples below; and analyzed by light microscopy or electron microscopy, for internalization as well as the location of the internalized antibody in the cell. For internalization in vitro, the cells can be incubated in tissue culture dishes in the presence or absence of the relevant antibodies added to the culture media and processed for microscopic analysis at desired time points. The presence of an internalized, labeled antibody in the cells can be directly visualized by microscopy or by autoradiography if radiolabeled antibody is used. Alternatively, in a quantitative biochemical assay, a population of cells comprising Cln101-expressing cells are contacted in vitro or in vivo with a radiolabeled test antibody and the cells (if contacted in vivo, cells are then isolated after a suitable amount of time) are treated with a protease or subjected to an acid wash to remove uninternalized antibody on the cell surface. The cells are ground up and the amount of protease resistant, radioactive counts per minute (cpm) associated with each

batch of cells is measured by passing the homogenate through a scintillation counter.

Based on the known specific activity of the radiolabeled antibody, the number of antibody molecules internalized per cell can be deduced from the scintillation counts of the ground-up cells. Cells are "contacted" with antibody in vitro preferably in solution form such as

5 by adding the cells to the cell culture media in the culture dish or flask and mixing the antibody well with the media to ensure uniform exposure of the cells to the antibody.

Instead of adding to the culture media, the cells can be contacted with the test antibody in an isotonic solution such as PBS in a test tube for the desired time period. In vivo, the cells are contacted with antibody by any suitable method of administering the test antibody

10 such as the methods of administration described below when administered to a patient.

The faster the rate of internalization of the antibody upon binding to the Cln101-expressing cell in vivo, the faster the desired killing or growth inhibitory effect on the target Cln101-expressing cell can be achieved, e.g., by a cytotoxic immunoconjugate.

15 Preferably, the kinetics of internalization of the anti-Cln101 antibodies are such that they favor rapid killing of the Cln101-expressing target cell. Therefore, it is desirable that the anti-Cln101 antibody exhibit a rapid rate of internalization preferably, within 24 hours from administration of the antibody in vivo, more preferably within about 12 hours, even more preferably within about 30 minutes to 1 hour, and most preferably, within about 30 minutes. The present invention provides antibodies that internalize as fast as about 15

20 minutes from the time of introducing the anti-Cln101 antibody in vivo. The antibody will preferably be internalized into the cell within a few hours upon binding to Cln101 on the cell surface, preferably within 1 hour, even more preferably within 15-30 minutes.

To determine if a test antibody can compete for binding to the same epitope as the epitope bound by the anti-Cln101 antibodies of the present invention including the

25 antibodies produced by the hybridomas deposited with the ATCC, a cross-blocking assay e.g., a competitive ELISA assay can be performed. In an exemplary competitive ELISA assay, Cln101-coated wells of a microtiter plate, or Cln101-coated sepharose beads, are pre-incubated with or without candidate competing antibody and then a biotin-labeled anti-Cln101 antibody of the invention is added. The amount of labeled anti-Cln101

30 antibody bound to the Cln101 antigen in the wells or on the beads is measured using avidin-peroxidase conjugate and appropriate substrate.

Alternatively, the anti-Cln101 antibody can be labeled, e.g., with a radioactive or fluorescent label or some other detectable and measurable label. The amount of labeled anti-Cln101 antibody that binds to the antigen will have an inverse correlation to the ability of the candidate competing antibody (test antibody) to compete for binding to the same epitope on the antigen, i.e., the greater the affinity of the test antibody for the same epitope, the less labeled anti-Cln101 antibody will be bound to the antigen-coated wells. A candidate competing antibody is considered an antibody that binds substantially to the same epitope or that competes for binding to the same epitope as an anti-Cln101 antibody of the invention if the candidate competing antibody can block binding of the anti-Cln101 antibody by at least 20%, preferably by at least 20-50%, even more preferably, by at least 50% as compared to a control performed in parallel in the absence of the candidate competing antibody (but may be in the presence of a known noncompeting antibody). It will be understood that variations of this assay can be performed to arrive at the same quantitative value.

An antibody having a "biological characteristic" of a designated antibody, such as any of the monoclonal antibodies Cln101.A1.1, Cln101.A3.1, Cln101.A6.1, Cln101.A7.1, Cln101.A8.1, Cln101.A9.1, Cln101.A10.1, Cln101.A11.1, Cln101.A15.1, Cln101.A16, Cln101.A17.1, Cln101.A18.1, Cln101.A23.1, Cln101.A26.1, Cln101.A28.1, Cln101.A35.1, Cln101.A37.1, Cln101.A38.1, Cln101.A41.1, Cln101.A42.1, Cln101.A46.1, Cln101.A47.1, Cln101.C3, Cln101.C6, Cln101.C12, Cln101.C17, Cln101.C18, Cln101.C25, Cln101.C36, Cln101.C43 and Cln101.C47, is one which possesses one or more of the biological characteristics of that antibody which distinguish it from other antibodies that bind to the same antigen, Cln101.A1.1, Cln101.A3.1, Cln101.A6.1, Cln101.A7.1, Cln101.A8.1, Cln101.A9.1, Cln101.A10.1, Cln101.A11.1, Cln101.A15.1, Cln101.A16, Cln101.A17.1, Cln101.A18.1, Cln101.A23.1, Cln101.A26.1, Cln101.A28.1, Cln101.A35.1, Cln101.A37.1, Cln101.A38.1, Cln101.A41.1, Cln101.A42.1, Cln101.A46.1, Cln101.A47.1, Cln101.C3, Cln101.C6, Cln101.C12, Cln101.C17, Cln101.C18, Cln101.C25, Cln101.C36, Cln101.C43 and Cln101.C47 will bind the same epitope as that bound by Cln101.A1.1, Cln101.A3.1, Cln101.A6.1, Cln101.A7.1, Cln101.A8.1, Cln101.A9.1, Cln101.A10.1, Cln101.A11.1, Cln101.A15.1, Cln101.A16, Cln101.A17.1, Cln101.A18.1, Cln101.A23.1, Cln101.A26.1, Cln101.A28.1, Cln101.A35.1, Cln101.A37.1, Cln101.A38.1, Cln101.A41.1, Cln101.A42.1,

Cln101.A46.1, Cln101.A47.1, Cln101.C3, Cln101.C6, Cln101.C12, Cln101.C17, Cln101.C18, Cln101.C25, Cln101.C36, Cln101.C43 and Cln101.C47 (e.g. which competes for binding or blocks binding of monoclonal antibody Cln101.A1.1, Cln101.A3.1, Cln101.A6.1, Cln101.A7.1, Cln101.A8.1, Cln101.A9.1, Cln101.A10.1, 5 Cln101.A11.1, Cln101.A15.1, Cln101.A16, Cln101.A17.1, Cln101.A18.1, Cln101.A23.1, Cln101.A26.1, Cln101.A28.1, Cln101.A35.1, Cln101.A37.1, Cln101.A38.1, Cln101.A41.1, Cln101.A42.1, Cln101.A46.1, Cln101.A47.1, Cln101.C3, Cln101.C6, Cln101.C12, Cln101.C17, Cln101.C18, Cln101.C25, Cln101.C36, Cln101.C43 and Cln101.C47 to Cln101), be able to target an Cln101-expressing tumor cell in vivo and 10 will bind to Cln101 on a mammalian cell in vivo. It is noted that the nomenclature format for anti-Cln101 antibodies may also be represented without the first punctuation point “.”. For example Cln101.A9.1 and Cln101.A46.1 may be represented as Cln101 A9.1 and Cln101 A46.1, respectively.

Furthermore, an antibody with the biological characteristic of the Cln101.A1.1, 15 Cln101.A3.1, Cln101.A6.1, Cln101.A7.1, Cln101.A8.1, Cln101.A9.1, Cln101.A10.1, Cln101.A11.1, Cln101.A15.1, Cln101.A16, Cln101.A17.1, Cln101.A18.1, Cln101.A23.1, Cln101.A26.1, Cln101.A28.1, Cln101.A35.1, Cln101.A37.1, Cln101.A38.1, Cln101.A41.1, Cln101.A42.1, Cln101.A46.1, Cln101.A47.1, Cln101.C3, Cln101.C6, Cln101.C12, Cln101.C17, Cln101.C18, Cln101.C25, Cln101.C36, Cln101.C43 and 20 Cln101.C47 antibody will internalize upon binding to Cln101 on a mammalian cell in vivo.

Likewise, an antibody with the biological characteristic of the Cln101.A1.1, Cln101.A3.1, Cln101.A6.1, Cln101.A7.1, Cln101.A8.1, Cln101.A9.1, Cln101.A10.1, Cln101.A11.1, Cln101.A15.1, Cln101.A16, Cln101.A17.1, Cln101.A18.1, Cln101.A23.1, 25 Cln101.A26.1, Cln101.A28.1, Cln101.A35.1, Cln101.A37.1, Cln101.A38.1, Cln101.A41.1, Cln101.A42.1, Cln101.A46.1, Cln101.A47.1, Cln101.C3, Cln101.C6, Cln101.C12, Cln101.C17, Cln101.C18, Cln101.C25, Cln101.C36, Cln101.C43 and Cln101.C47 antibody will have the same epitope binding, targeting, internalizing, tumor growth inhibitory and cytotoxic properties of the antibody.

30 The term "antagonist" antibody is used in the broadest sense, and includes an antibody that partially or fully blocks, inhibits, or neutralizes a biological activity of a native Cln101 protein disclosed herein. Methods for identifying antagonists of an Cln101

polypeptide may comprise contacting an Cln101 polypeptide or a cell expressing Cln101 on the cell surface, with a candidate antagonist antibody and measuring a detectable change in one or more biological activities normally associated with the Cln101 polypeptide.

5           An "antibody that inhibits the growth of tumor cells expressing Cln101" or a "growth inhibitory" antibody is one which binds to and results in measurable growth inhibition of cancer cells expressing or overexpressing Cln101. Alternatively, an antibody that inhibits the growth of tumor cells expressing Cln101 or a growth inhibitory antibody is one which binds to and inhibits the function of Cln101 which results in measurable  
10 growth inhibition of cancer cells expressing or overexpressing Cln101. Preferred growth inhibitory anti-Cln101 antibodies inhibit growth of Cln101-expressing tumor cells e.g., prostate or ovarian cancer cells) by greater than 20%, preferably from about 20% to about 50%, and even more preferably, by greater than 50% (e.g. from about 50% to about 100%) as compared to the appropriate control, the control typically being tumor cells not treated  
15 with the antibody being tested. Growth inhibition can be measured at an antibody concentration of about 0.1 to 30 pg/ml or about 0.5 nM to 200 nM in cell culture, where the growth inhibition is determined 1-10 days after exposure of the tumor cells to the antibody. Growth inhibition of tumor cells in vivo can be determined in various ways such as is described in the Experimental Examples section below. The antibody is growth  
20 inhibitory in vivo if administration of the anti-Cln101 antibody at about 1 pg/kg to about 100 mg/kg body weight results in reduction in tumor size or tumor cell proliferation within about 5 days to 3 months from the first administration of the antibody, preferably within about 5 to 30 days.

          An antibody which "induces apoptosis" is one which induces programmed cell  
25 death as determined by binding of annexin V, fragmentation of DNA, cell shrinkage, dilation of endoplasmic reticulum, cell fragmentation, and/or formation of membrane vesicles (called apoptotic bodies). The cell is usually one which overexpresses Cln101. Preferably the cell is a tumor cell, e.g. an prostate or ovarian cell. Various methods are available for evaluating the cellular events associated with apoptosis. For example,  
30 phosphatidyl serine (PS) translocation can be measured by annexin binding; DNA fragmentation can be evaluated through DNA laddering; and nuclear/chromatin condensation along with DNA fragmentation can be evaluated by any increase in

hypodiploid cells. Preferably, the antibody which induces apoptosis is one which results in about 2 to 50 fold, preferably about 5 to 50 fold, and most preferably about 10 to 50 fold, induction of annexin binding relative to untreated cells in an annexin binding assay.

Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.

"Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted Ig bound onto Fc receptors (FcRs) present on certain cytotoxic cells (e.g. Natural Killer (NK) cells, neutrophils, and macrophages) enable these cytotoxic effector cells to bind specifically to an antigen bearing target cell and subsequently kill the target cell with cytotoxins. The antibodies "arm" the cytotoxic cells and are absolutely required for such killing. The primary cells for mediating ADCC, NK cells, express FcγRIII only, whereas monocytes express FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, *Annu. Rev. Immunol* 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in US Patent No. 5,500,362 or 5,821,337 may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al. *PNAS (USA)* 95:652-656 (1998).

"Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. The preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA (an "activating receptor") and FcγRIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif

(ITIM) in its cytoplasmic domain. (see review M. in Daeron, *Annu. Rev. Immunol.* 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, *Annu. Rev. Immunol* 9:457-92 (1991); Capel et al., *Immunomethods* 4:25-34 (1994); and de Haas et al., *J. Lab. Clin. Med.* 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer, of maternal IgGs to the fetus (Guyer et al., *J. Immunol.* 117:587 (1976) and Kim et al., *J. Immunol.* 24:249 (1994)).

"Human effector cells" are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least FcγRIII and perform ADCC effector function. Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils; with PBMCs and NK cells being preferred. The effector cells may be isolated from a native source, e.g. from blood.

"Complement dependent cytotoxicity" or "CDC" refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to antibodies (of the appropriate subclass) which are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g. as described in Gazzano-Santoro et al., *J. Immunol. Methods* 202:163 (1996) may be performed.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g. epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, melanoma, multiple

myeloma and B-cell lymphoma, brain , as well as head and neck cancer, and associated metastases.

A "Cln101-expressing cell" is a cell which expresses secreted endogenous or transfected Cln101. A "Cln101-expressing cancer" is a cancer comprising cells that secrete  
5 Cln101 protein from the cells. A "Cln101-expressing cancer" produces sufficient levels of Cln101 such that an anti-Cln101 antibody can bind thereto and have a therapeutic effect with respect to the cancer. A cancer which "overexpresses" Cln101 is one which has significantly higher levels of Cln101 compared to a noncancerous cell of the same tissue type. Such overexpression may be caused by gene amplification or by increased  
10 transcription or translation. Cln101 overexpression may be determined in a diagnostic or prognostic assay by evaluating increased levels of the Cln101 protein (e.g. via an immunohistochemistry assay; FACS analysis). Alternatively, or additionally, one may measure levels of Cln101-encoding nucleic acid or mRNA in the cell, e.g. via fluorescent in situ hybridization; (FISH; see W098/45479 published October, 1998), Southern  
15 blotting, Northern blotting, or polymerase chain reaction (PCR) techniques, such as real time quantitative PCR (RT-PCR). One may also study Cln101 overexpression by measuring the antigen in a biological fluid such as serum, e.g., using antibody-based assays (see also, e.g., U.S. Patent No. 4,933,294 issued June 12, 1990; W091/05264 published April 18, 1991; U.S. Patent 5,401,638 issued March 28, 1995; and Sias et al. J.  
20 Immunol. Methods 132: 73-80 (1990)). Biological or bodily fluids further include blood, serum, saliva, urine, sputum, seminal fluids, and other bodily excretions such as stool. Aside from the above assays, various in vivo assays are available to the skilled practitioner. For example, one may expose cells or tissues within the body of the patient to an antibody which is optionally labeled with a detectable label, e.g. a radioactive isotope,  
25 and binding of the antibody to cells in the patient can be evaluated, e.g. by external scanning for radioactivity or by analyzing a biopsy taken from a patient previously exposed to the antibody. A Cln101-expressing cancer includes ovarian, pancreatic, lung or breast cancer.

A "mammal" for purposes of treating a cancer or alleviating the symptoms of  
30 cancer, refers to any mammal, including-humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.

"Treating" or "treatment" or "alleviation" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. A subject or mammal is successfully "treated" for an Cln101-expressing cancer if, after receiving a therapeutic amount of an anti-Cln101 antibody according to the methods of the present invention, the patient shows observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of cancer cells or absence of the cancer cells; reduction in the tumor size; inhibition (i.e., slow to some extent and preferably stop) of cancer cell infiltration into peripheral organs including the spread of cancer into soft tissue and bone; inhibition (i.e., slow to some extent and preferably stop) of tumor metastasis; inhibition, to some extent, of tumor growth; and/or relief to some extent, one or more of the symptoms associated with the specific cancer; reduced morbidity and mortality, and improvement in quality of life issues. To the extent the anti-Cln101 antibody may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. Reduction of these signs or symptoms may also be felt by the patient.

The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician. For cancer therapy, efficacy can be measured, for example, by assessing the time to disease progression (TTP) and/or determining the response rate (RR).

The term "therapeutically effective amount" refers to an amount of an antibody or a drug effective to "treat" a disease or disorder in a subject or mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. See preceding definition of "treating". To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.

"Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time.

"Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed.

Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN<sup>TM</sup>, polyethylene glycol (PEG), and PLURONICS<sup>TM</sup>.

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g. At<sup>211</sup>, I<sup>131</sup>, I<sup>125</sup>, Y<sup>90</sup>, Re<sup>186</sup>, Re<sup>188</sup>, Sm<sup>153</sup>, Bi<sup>212</sup>, P<sup>32</sup>, and radioactive isotopes of Lu), chemotherapeutic agents e.g. methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof, e.g., gelonin, ricin, saporin, and the various antitumor or anticancer agents disclosed below. Other cytotoxic agents are described below. A tumoricidal agent causes destruction of tumor cells.

A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, especially an Cln101-expressing cancer cell, either in vitro or in vivo. Thus, the growth inhibitory agent may be one which significantly reduces the percentage of Cln101-expressing cells in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxanes, and topoisomerase II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs" by Murakami et al. (WB Saunders: Philadelphia, 1995), especially p. 13. The taxanes (paclitaxel and docetaxel) are anticancer drugs both derived from the yew tree. Docetaxel (TAXOTERE®, Rhone-Poulenc Rorer), derived from the European yew, is a semisynthetic analogue of paclitaxel (TAXOL®, Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, which results in the inhibition of mitosis in cells.

"Label" as used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

The term "epitope tagged" used herein refers to a chimeric polypeptide comprising an anti-Cln101 antibody polypeptide fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the Ig polypeptide to which it is fused. The tag polypeptide is also preferably fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

A "small molecule" is defined herein to have a molecular weight below about 500 Daltons.

The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.

An "isolated nucleic acid molecule" is a nucleic acid molecule, e.g., an RNA, DNA, or a mixed polymer, which is substantially separated from other genome DNA sequences as well as proteins or complexes such as ribosomes and polymerases, which naturally accompany a native sequence. The term embraces a nucleic acid molecule which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogues or analogues biologically synthesized by heterologous systems. A substantially pure nucleic acid molecule includes isolated forms of the nucleic acid molecule.

"Vector" includes shuttle and expression vectors and includes, e.g., a plasmid, cosmid, or phagemid. Typically, a plasmid construct will also include an origin of replication (e.g., the ColEI origin of replication) and a selectable marker (e.g., ampicillin or tetracycline resistance), for replication and selection, respectively, of the plasmids in bacteria. An "expression vector" refers to a vector that contains the necessary control sequences or regulatory elements for expression of the antibodies including antibody fragment of the invention, in prokaryotic, e.g., bacterial, or eukaryotic cells. Suitable vectors are disclosed below.

The cell that produces an anti-Cln101 antibody of the invention will include the parent hybridoma cell e.g., the hybridomas that are deposited with the ATCC, as well as bacterial and eukaryotic host cells into which nucleic acid encoding the antibodies have been introduced. Suitable host cells are disclosed below.

RNA interference refers to the process of sequence-specific post transcriptional gene silencing in animals mediated by short interfering RNAs (siRNA) (Fire et al., 1998, Nature, 391, 806). The corresponding process in plants is commonly referred to as post transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post transcriptional gene silencing is thought to be an evolutionarily conserved cellular defense mechanism used to prevent the expression of foreign genes

which is commonly shared by diverse flora and phyla (Fire et al., 1999, Trends Genet., 15, 358). Such protection from foreign gene expression may have evolved in response to the production of double stranded RNAs (dsRNA) derived from viral infection or the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response through a mechanism that has yet to be fully characterized. This mechanism appears to be different from the interferon response that results from dsRNA mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

10 The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNA) (Bernstein et al., 2001, Nature, 409, 363). Short interfering RNAs derived from dicer activity are typically about 21-23 nucleotides in length and comprise about 19 base pair duplexes. Dicer has also been  
15 implicated in the excision of 21 and 22 nucleotide small temporal RNAs (stRNA) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner et al., 2001, Science, 293, 834). The RNAi response also features an endonuclease complex containing a siRNA, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single stranded RNA having  
20 sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex (Elbashir et al., 2001, Genes Dev., 15, 188).

Short interfering RNA mediated RNAi has been studied in a variety of systems. Fire et al., 1998, Nature, 391, 806, were the first to observe RNAi in *C. Elegans*. Wianny and Goetz, 1999, Nature Cell Biol., 2, 70, describe RNAi mediated by dsRNA in mouse  
25 embryos. Hammond et al., 2000, Nature, 404, 293, describe RNAi in *Drosophila* cells transfected with dsRNA. Elbashir et al., 2001, Nature, 411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in *Drosophila* embryonic  
30 lysates (Elbashir et al., 2001, EMBO J., 20, 6877) has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown that 21 nucleotide siRNA duplexes are

most active when containing two nucleotide 3'-overhangs. Furthermore, complete substitution of one or both siRNA strands with 2'-deoxy (2'-H) or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of the 3'-terminal siRNA overhang nucleotides with deoxy nucleotides (2'-H) was shown to be tolerated. Single mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end (Elbashir et al., 2001, EMBO J., 20, 6877). Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that ATP is utilized to maintain the 5'-phosphate moiety on the siRNA (Nykanen et al., 2001, Cell, 107, 309).

Studies have shown that replacing the 3'-overhanging segments of a 21-mer siRNA duplex having 2 nucleotide 3' overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to 4 nucleotides on each end of the siRNA with deoxyribonucleotides has been reported to be well tolerated whereas complete substitution with deoxyribonucleotides results in no RNAi activity (Elbashir et al., 2001, EMBO J., 20, 6877). In addition, Elbashir et al., supra, also report that substitution of siRNA with 2'-O-methyl nucleotides completely abolishes RNAi activity. Li et al., International PCT Publication No. WO 00/44914, and Beach et al., International PCT Publication No. WO 01/68836 both suggest that siRNA "may include modifications to either the phosphate-sugar back bone or the nucleoside to include at least one of a nitrogen or sulfur heteroatom", however neither application teaches to what extent these modifications are tolerated in siRNA molecules nor provide any examples of such modified siRNA. Kreutzer and Limmer, Canadian Patent Application No. 2,359,180, also describe certain chemical modifications for use in dsRNA constructs in order to counteract activation of double stranded-RNA-dependent protein kinase PKR, specifically 2'-amino or 2'-O-methyl nucleotides, and nucleotides containing a 2'-O or 4'-C methylene bridge. However, Kreutzer and Limmer similarly fail to show to what extent these modifications are tolerated in siRNA molecules nor do they provide any examples of such modified siRNA.

Parrish et al., 2000, Molecular Cell, 6, 1977-1087, tested certain chemical modifications targeting the unc-22 gene in *C. elegans* using long (>25 nt) siRNA

transcripts. The authors describe the introduction of thiophosphate residues into these siRNA transcripts by incorporating thiophosphate nucleotide analogs with T7 and T3 RNA polymerase and observed that "RNAs with two (phosphorothioate) modified bases also had substantial decreases in effectiveness as RNAi triggers (data not shown);

5 (phosphorothioate) modification of more than two residues greatly destabilized the RNAs in vitro and we were not able to assay interference activities." Id. at 1081. The authors also tested certain modifications at the 2'-position of the nucleotide sugar in the long siRNA transcripts and observed that substituting deoxynucleotides for ribonucleotides "produced a substantial decrease in interference activity", especially in the case of Uridine to

10 Thymidine and/or Cytidine to deoxy-Cytidine substitutions. Id. In addition, the authors tested certain base modifications, including substituting 4-thiouracil, 5-bromouracil, 5-iodouracil, 3-(aminoallyl)uracil for uracil, and inosine for guanosine in sense and antisense strands of the siRNA, and found that whereas 4-thiouracil and 5-bromouracil were all well tolerated, inosine "produced a substantial decrease in interference activity"

15 when incorporated in either strand. Incorporation of 5-iodouracil and 3-(aminoallyl)uracil in the antisense strand resulted in substantial decrease in RNAi activity as well.

Beach et al., International PCT Publication No. WO 01/68836, describes specific methods for attenuating gene expression using endogenously derived dsRNA. Tuschl et al., International PCT Publication No. WO 01/75164, describes a *Drosophila* in vitro

20 RNAi system and the use of specific siRNA molecules for certain functional genomic and certain therapeutic applications; although Tuschl, 2001, *Chem. Biochem.*, 2, 239-245, doubts that RNAi can be used to cure genetic diseases or viral infection due "to the danger of activating interferon response". Li et al., International PCT Publication No. WO 00/44914, describes the use of specific dsRNAs for use in attenuating the expression of

25 certain target genes. Zernicka-Goetz et al., International PCT Publication No. WO 01/36646, describes certain methods for inhibiting the expression of particular genes in mammalian cells using certain dsRNA molecules. Fire et al., International PCT Publication No. WO 99/32619, describes particular methods for introducing certain dsRNA molecules into cells for use in inhibiting gene expression. Plaetinck et al.,

30 International PCT Publication No. WO 00/01846, describes certain methods for identifying specific genes responsible for conferring a particular phenotype in a cell using specific dsRNA molecules. Mello et al., International PCT Publication No. WO 01/29058,

describes the identification of specific genes involved in dsRNA mediated RNAi. Deschamps Depaillette et al., International PCT Publication No. WO 99/07409, describes specific compositions consisting of particular dsRNA molecules combined with certain anti-viral agents. Driscoll et al., International PCT Publication No. WO 01/49844, describes specific DNA constructs for use in facilitating gene silencing in targeted organisms. Parrish et al., 2000, Molecular Cell, 6, 1977-1087, describes specific chemically modified siRNA constructs targeting the unc-22 gene of *C. elegans*. Tuschl et al., International PCT Publication No. WO 02/44321, describe certain synthetic siRNA constructs.

#### 10 Compositions and Methods of the Invention

The invention provides anti-Cln101 antibodies. Preferably, the anti-Cln101 antibodies bind to Cln101 in vivo or in a mammalian bodily fluid. Alternatively, the anti-Cln101 antibodies internalize upon binding to cell surface Cln101 on a mammalian cell. The anti-Cln101 antibodies may also destroy or lead to the destruction of tumor cells bearing or secreting Cln101.

It was not apparent that Cln101 was internalization-competent. In addition the ability of an antibody to internalize depends on several factors including the affinity, avidity, and isotype of the antibody, and the epitope that it binds. We have demonstrated herein that the cell surface Cln101 is internalization competent upon binding by the anti-Cln101 antibodies of the invention. Additionally, it was demonstrated that the anti-Cln101 antibodies of the present invention can specifically target Cln101-expressing tumor cells in vivo and inhibit or kill these cells. These in vivo tumor targeting, internalization and growth inhibitory properties of the anti-Cln101 antibodies make these antibodies very suitable for therapeutic uses, e.g., in the treatment of various cancers including prostate or ovarian cancer. Internalization of the anti-Cln101 antibody is preferred, e.g., if the antibody or antibody conjugate has an intracellular site of action and if the cytotoxic agent conjugated to the antibody does not readily cross the plasma membrane (e.g., the toxin calicheamicin). Internalization is not necessary if the antibodies or the agent conjugated to the antibodies do not have intracellular sites of action, e.g., if the antibody can kill the tumor cell by ADCC or some other mechanism.

The anti-Cln101 antibodies of the invention also have various non-therapeutic applications. The anti-Cln101 antibodies of the present invention can be useful for

diagnosis and staging of Cln101-expressing cancers (e.g., in radioimaging). They may be used alone or in combination with other ovarian cancer markers, including, but not limited to, CA125, HE4 and mesothelin. The anti-Cln101 antibodies of the present invention may also be used alone or in combination with other prostate cancer markers, including, but not  
5 limited to Prostate Specific Antigen (PSA). The antibodies are also useful for purification or immunoprecipitation of Cln101 from cells or bodily fluids, for detection and quantitation of Cln101 in vitro, e.g. in an ELISA or a Western blot, to kill and eliminate Cln101-expressing cells from a population of mixed cells as a step in the purification of other cells. The anti-Cln101 antibodies of the invention can be in the different forms  
10 encompassed by the definition of "antibody" herein. Thus, the antibodies include full length or intact antibody, antibody fragments, native sequence antibody or amino acid variants, humanized, chimeric or fusion antibodies, immunoconjugates, and functional fragments thereof. In fusion antibodies, an antibody sequence is fused to a heterologous polypeptide sequence. The antibodies can be modified in the Fc region to provide desired  
15 effector functions. As discussed in more detail in the sections below, with the appropriate Fc regions, the naked antibody bound on the cell surface can induce cytotoxicity, e.g., via antibody-dependent cellular cytotoxicity (ADCC) or by recruiting complement in complement dependent cytotoxicity, or some other mechanism. Alternatively, where it is desirable to eliminate or reduce effector function, so as to minimize side effects or  
20 therapeutic complications, certain other Fc regions may be used.

The antibody may compete for binding, or binds substantially to, the same epitope bound by the antibodies of the invention. Antibodies having the biological characteristics of the present anti-Cln101 antibodies of the invention are also contemplated, e.g., an anti-Cln101 antibody which has the biological characteristics of a monoclonal antibody  
25 produced by the hybridomas accorded ATCC accession numbers PTA-5877 and PTA-5876, specifically including the in vivo tumor targeting, internalization and any cell proliferation inhibition or cytotoxic characteristics. Specifically provided are anti-Cln101 antibodies that bind to an epitope present in amino acids 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-158 of human  
30 Cln101.

Methods of producing the above antibodies are described in detail below.

The present anti-Cln101 antibodies are useful for treating a Cln101-expressing cancer or alleviating one or more symptoms of the cancer in a mammal. Such a cancer includes prostate or ovarian cancer, cancer of the urinary tract, breast cancer, lung cancer, and colon cancer. Such a cancer includes more specifically, ovarian serous  
5 adenocarcinoma, breast infiltrating ductal carcinoma, prostate adenocarcinoma, renal cell carcinomas, colorectal adenocarcinomas, lung adenocarcinomas, lung squamous cell carcinomas, and pleural mesothelioma. The breast cancer may be HER-2 negative or positive breast cancer. The cancers encompass metastatic cancers of any of the preceding, e.g., prostate or ovarian cancer metastases. The antibody is able to bind to at least a  
10 portion of the cancer cells that express Cln101 in the mammal and preferably is one that does not induce or that minimizes HAMA response. Preferably, the antibody is effective to destroy or kill Cln101-expressing tumor cells or inhibit the growth or proliferation of such tumor cells, in vitro or in vivo, upon binding to Cln101 on the cell. Alternatively, the antibody is effective to destroy or kill Cln101-expressing tumor cells or inhibit the growth  
15 or proliferation of such tumor cells, in vitro or in vivo, upon binding to secreted Cln101 in proximity to such tumor cells. Such an antibody includes a naked anti-Cln101 antibody (not conjugated to any agent). Such naked anti-Cln101 antibodies may inhibit Cln101 function or activity upon binding. Naked anti-Cln101 antibodies having tumor growth inhibition properties in vivo include the antibodies described in the Experimental  
20 Examples below. Naked antibodies that have cytotoxic or cell growth inhibition properties can be further conjugated with a cytotoxic agent to render them even more potent in tumor cell destruction. Cytotoxic properties can be conferred to an anti-Cln101 antibody by, e.g., conjugating the antibody with a cytotoxic agent, to form an immunoconjugate as described below. The cytotoxic agent or a growth inhibitory agent is preferably a small molecule.  
25 Toxins such as maytansin, maytansinoids, saporin, gelonin, ricin or calicheamicin and analogs or derivatives thereof, are preferable.

The invention provides a composition comprising an anti-Cln101 antibody of the invention, and a carrier. For the purposes of treating cancer, compositions can be administered to the patient in need of such treatment, wherein the composition can  
30 comprise one or more anti-Cln101 antibodies present as an immunoconjugate or as the naked antibody. Further, the compositions can comprise these antibodies in combination with other therapeutic agents such as cytotoxic or growth inhibitory agents, including

chemotherapeutic agents. The invention also provides formulations comprising an anti-Cln101 antibody of the invention, and a carrier. The formulation may be a therapeutic formulation comprising a pharmaceutically acceptable carrier.

Another aspect of the invention is isolated nucleic acids encoding the anti-Cln101  
5 antibodies. Nucleic acids encoding both the H and L chains and especially the hypervariable region residues, chains which encode the native sequence antibody as well as variants, modifications and humanized versions of the antibody, are encompassed.

The invention also provides methods useful for treating a Cln101-expressing cancer or alleviating one or more symptoms of the cancer in a mammal, comprising  
10 administering a therapeutically effective amount of an anti-Cln101 antibody to the mammal. The antibody therapeutic compositions can be administered short term (acute) or chronic, or intermittent as directed by physician. Also provided are methods of inhibiting the growth of, and killing a Cln101 expressing cell. Finally, the invention also provides kits and articles of manufacture comprising at least one antibody of this invention,  
15 preferably at least one anti-Cln101 antibody of this invention that binds to Cln101 in vivo or in a mammalian bodily fluid or at least one internalizing anti-Cln101 antibody of this invention.. Kits containing anti-Cln101 antibodies find use in detecting Cln101 expression, or in therapeutic or diagnostic assays, e.g., for Cln101 cell killing assays or for purification and/or immunoprecipitation of Cln101 from cells. For example, for isolation  
20 and purification of Cln101, the kit can contain an anti-Cln101 antibody coupled to a solid support, e.g., a tissue culture plate or beads (e.g., sepharose beads). Kits can be provided which contain antibodies for detection and quantitation of Cln101 in vitro, e.g. in an ELISA or a Western blot. Such antibody useful for detection may be provided with a label such as a fluorescent or radiolabel.

#### 25 Production of anti-Cln101 antibodies

The following describes exemplary techniques for the production of the antibodies useful in the present invention. Some of these techniques are described further in Example 1. The Cln101 antigen to be used for production of antibodies may be, e.g., the full length polypeptide or a portion thereof, including a soluble form of Cln101 lacking the signal  
30 peptide, a soluble form of recombinant Cln101 with a signal peptide or synthetic peptides to selected portions of the protein.

- Alternatively, cells expressing Cln101 at their cell surface (e.g. CHO or NIH-3T3 cells transformed to overexpress Cln101; ovarian, pancreatic, lung, breast or other Cln101-expressing tumor cell line), or membranes prepared from such cells can be used to generate antibodies. The nucleotide and amino acid sequences of human and murine Cln101 are available as provided above. Cln101 can be produced recombinantly in and isolated from, prokaryotic cells, e.g., bacterial cells, or eukaryotic cells using standard recombinant DNA methodology. Cln101 can be expressed as a tagged (e.g., epitope tag) or other fusion protein to facilitate its isolation as well as its identification in various assays.
- Antibodies or binding proteins that bind to various tags and fusion sequences are available as elaborated below. Other forms of Cln101 useful for generating antibodies will be apparent to those skilled in the art.

#### *Tags*

- Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 (Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein Engineering, 3(6):547-553 (1990)). The FLAG-peptide (Hopp et al., BioTechnology, 6:1204-1210 (1988)) is recognized by an anti-FLAG M2 monoclonal antibody (Eastman Kodak Co., New Haven, CT). Purification of a protein containing the FLAG peptide can be performed by immunoaffinity chromatography using an affinity matrix comprising the anti-FLAG M2 monoclonal antibody covalently attached to agarose (Eastman Kodak Co., New Haven, CT). Other tag polypeptides include the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an  $\alpha$ -tubulin epitope peptide (Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)); and the T7 gene protein peptide tag (Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)).

#### *Polyclonal Antibodies*

- Polyclonal antibodies are preferably raised in animals, preferably non-human animals, by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant

antigen and an adjuvant. It may be useful to conjugate the relevant antigen (especially when synthetic peptides are used) to a protein that is immunogenic in the species to be immunized. For example, the antigen can be conjugated to keyhole limpet hemocyanin (KLH), serum, bovine thyroglobulin, or soybean trypsin inhibitor, using a bifunctional or  
5 derivatizing agent, e.g., maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride,  $\text{SOCl}_2$ , or  $\text{R}^1\text{N}=\text{C}=\text{NR}$ , where R and  $\text{R}^1$  are different alkyl groups. Conjugates also can be made in recombinant cell culture as protein fusions.

Animals are immunized against the antigen, immunogenic conjugates, or  
10 derivatives by combining, e.g., 5-100 pg of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later, the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later, the animals are bled and  
15 the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Also, aggregating agents such as alum are suitably used to enhance the immune response.

#### *Monoclonal Antibodies*

Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., *Nature*, 256:495 (1975), or may be made by recombinant DNA methods  
20 (U.S. Patent No. 4,816,567). In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, is immunized as described above to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. After immunization, lymphocytes are isolated and then fused with a "fusion partner", e.g., a  
25 myeloma cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies. Principles and Practice*, pp 103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitable culture medium which medium preferably contains one or more substances that inhibit the growth  
30 or survival of the unfused, fusion partner, e.g., the parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the selective culture medium for the hybridomas typically

will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Preferred fusion partner myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a selective medium that selects against the unfused parental cells. Preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 and derivatives e.g., X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); and Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis described in Munson et al., *Anal. Biochem.*, 107:220 (1980). Once hybridoma cells that produce antibodies of the desired specificity, affinity, and/or activity are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, *Monoclonal Antibodies: Principles and Practice*, pp 103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal e.g., by i.p. injection of the cells into mice.

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, affinity chromatography (e.g., using protein A or protein G-Sepharose) or ion-exchange chromatography, hydroxylapatite chromatography, gel electrophoresis, dialysis, etc.

DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be  
5 placed into expression vectors, which are then transformed or transfected into prokaryotic or eukaryotic host cells such as, e.g., E coli cells, simian COS cells, Chinese Hamster Ovary (CHO) cells, or myeloma cells, that do not otherwise produce antibody protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression in bacteria of DNA encoding the antibody include  
10 Skerra et al., *Curr. Opinion in Immunol.*, 5:256-262 (1993) and Phickthun, *Immunol. Revs.*, 130:151-188 (1992).

Further, the monoclonal antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., *Nature*, 348:552-554 (1990). Clackson et al., *Nature*, 352:624-628 (1991) and Marks et al.,  
15 *J. Mol. Biol.*, 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks et al., *Bio/Technology*, 10:779-783 (1992)), as well as combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries (Waterhouse et al.,  
20 *Nuc. Acids. Res.*, 21:2265-2266 (1993)). Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.

The DNA that encodes the antibody may be modified to produce chimeric or fusion antibody polypeptides, for example, by substituting human heavy chain and light  
25 chain constant domain (CH and CL) sequences for the homologous murine sequences (U.S. Patent No. 4,816,567; and Morrison, et al., *Proc. Natl Acad. Sci. USA*, 81:6851 (1984)), or by fusing the immunoglobulin coding sequence with all or part of the coding sequence for a non-immunoglobulin polypeptide (heterologous polypeptide). The nonimmunoglobulin polypeptide sequences can substitute for the constant domains of an  
30 antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site

having specificity for an antigen and another antigen-combining site having specificity for a different antigen.

### *Humanized Antibodies*

Methods for humanizing non-human antibodies have been described in the art.

5 Preferably, a humanized antibody has one or more amino acid residues introduced into it from a source which is nonhuman. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-10 327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting hypervariable region sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567) wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice,15 humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity and HAMA response20 (human anti-mouse antibody) when the antibody is intended for human therapeutic use. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human V domain sequence which is closest to that of the rodent is identified and the human framework region (FR) within it accepted for the humanized25 antibody (Sims et al., J. Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987)). Another method uses a particular framework region derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993)).

30 It is further important that antibodies be humanized with retention of high binding affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of

analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.

5           Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR  
10 residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in influencing antigen binding.

          Various forms of a humanized anti-Cln101 antibody are contemplated. For  
15 example, the humanized antibody may be an antibody fragment, such as a Fab, which is optionally conjugated with one or more cytotoxic agent(s) in order to generate an immunoconjugate. Alternatively, the humanized antibody may be an intact antibody, such as an intact IgG1 antibody.

#### *Human Antibodies*

20           As an alternative to humanization, human antibodies can be generated. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region ( $J_H$ ) gene in chimeric and  
25 germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array into such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Year in Immuno., 7:33 (1993); U.S. Patent Nos.  
30 5,545,806, 5,569,825, 5,591,669 (all of GenPharm); 5,545,807; and Alternatively, phage display technology (McCafferty et al., Nature 348:552-553 (1990)) can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V)

domain gene repertoires from unimmunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell. Phage display can be performed in a variety of formats, reviewed in, e.g., Johnson, Kevin S. and Chiswell, David J., *Current Opinion in Structural Biology* 3:564-571 (1993).

Several sources of V-gene segments can be used for phage display. Clackson et al., *Nature*, 352:624-628 (1991) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., *J. Mol. Biol.* 222:581-597 (1991), or Griffith et al., *EMBO J.* 12:725-734 (1993). See, also, U.S. Patent Nos. 5,565,332 and 5,573,905. As discussed above, human antibodies may also be generated by in vitro activated B cells (see U.S. Patents 5,567,610 and 5,229,275).

#### *Antibody Fragments*

In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. The smaller size of the fragments allows for rapid clearance, and may lead to improved access to solid tumors. Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., *Journal of Biochemical and Biophysical Methods* 24:107-117 (1992); and Brennan et al., *Science*, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Fab, Fv and ScFv antibody fragments can all be expressed in and secreted from *E. coli*, thus allowing the facile production of large amounts of these fragments. Antibody fragments can be isolated from the antibody phage libraries discussed above.

Alternatively, Fab'-SH fragments can be directly recovered from *E. coli* and chemically coupled to form F(ab)2 fragments (Carter et al., *Bio/Technology* 10: 163-167 (1992)). According to another approach, F(ab)2 fragments can be isolated directly from

recombinant host cell culture. Fab and F(ab)<sub>2</sub> fragment with increased in vivo half-life comprising a salvage receptor binding epitope residues are described in U.S. Patent No. 5,869,046. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. The antibody of choice may also be a single chain Fv fragment (scFv). See WO 93/16185; U.S. Patent No. 5,571,894; and U.S. Patent No. 5,587,458. Fv and sFv are the only species with intact combining sites that are devoid of constant regions; thus, they are suitable for reduced nonspecific binding during in vivo use. sFv fusion proteins may be constructed to yield fusion of an effector protein at either the amino or the carboxy terminus of an sFv. See Antibody Engineering, ed. Borrebaeck, supra. The antibody fragment may also be a "linear antibody", e.g., as described in U.S. Patent 5,641,870 for example. Such linear antibody fragments may be monospecific or bispecific.

#### *Bispecific Antibodies*

Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of the Cln101 protein. Other such antibodies may combine an Cln101 binding site with a binding site for another protein. Alternatively, an anti-Cln101.Arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a Tcell receptor molecule (e.g. C133), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16), so as to focus and localize cellular defense mechanisms to the Cln101-expressing cell. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express Cln101. These antibodies possess an Cln101-binding arm and an arm which binds the cytotoxic agent (e.g. saporin, anti-interferon-α, vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab)<sub>2</sub> bispecific antibodies). WO 96/16673 describes a bispecific anti-ErbB2/anti-FcγRIII antibody and U.S. Patent No. 5,837,234 discloses a bispecific anti-ErbB2/anti-FcγRI antibody. A bispecific anti-ErbB2/Fcα antibody is shown in WO98/02463. U.S. Patent No. 5,821,337 teaches a bispecific anti-ErbB2/anti-CD3 antibody.

Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different

specificities (Millstein *et al.*, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker *et al.*, *EMBO J.*, 10:3655-3659 (1991).

According to a different approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. Preferably, the fusion is with an Ig heavy chain constant domain, comprising at least part of the hinge, C<sub>H</sub>2, and C<sub>H</sub>3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light chain bonding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host cell. This provides for greater flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yield of the desired bispecific antibody. It is, however, possible to insert the coding sequences for two or all three polypeptide chains into a single expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios have no significant affect on the yield of the desired chain combination.

Preferably, the bispecific antibodies in this approach are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986).

According to another approach described in U.S. Patent No. 5,731,168, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 domain. In this method, one or  
5 more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the  
10 heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO  
15 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Patent No. 4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragments have also  
20 been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science, 229: 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')<sub>2</sub> fragments. These fragments are reduced in the presence of the dithiol complexing agent, sodium arsenite, to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab'  
25 fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

30 Recent progress has facilitated the direct recovery of Fab'-SH fragments from *E. coli*, which can be chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med., 175: 217-225 (1992) describe the production of a fully humanized bispecific

antibody F(ab')<sub>2</sub> molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.*, 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.

The "diabody" technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a VH connected to a VL by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (scFv) dimers has also been reported. See Gruber et al., *J. Immunol.*, 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al. *J. Immunol.* 147: 60 (1991).

#### *Multivalent Antibodies*

A multivalent antibody may be internalized (and/or catabolized) faster than a bivalent antibody by a cell expressing an antigen to which the antibodies bind. The antibodies of the present invention can be multivalent antibodies (which are other than of the IgM class) with three or more antigen binding sites (e.g. tetravalent antibodies), which can be readily produced by recombinant expression of nucleic acid encoding the polypeptide chains of the antibody. The multivalent antibody can comprise a dimerization domain and three or more antigen binding sites. The preferred dimerization domain comprises (or consists of) an Fc region or a hinge region. In this scenario, the antibody

will comprise an Fc region and three or more antigen binding sites amino-terminal to the Fc region. The preferred multivalent antibody herein comprises (or consists of) three to about eight, but preferably four, antigen binding sites. The multivalent antibody comprises at least one polypeptide chain (and preferably two polypeptide chains), wherein the

5 polypeptide chain(s) comprise two or more variable domains. For instance, the polypeptide chain(s) may comprise VDI(X1n-VD2-(X2)n)-Fc, wherein VDI is a first variable domain, VD2 is a second variable domain, Fc is one polypeptide chain of an Fc region, XI and X2 represent an amino acid or polypeptide, and n is 0 or 1. For instance, the polypeptide chain(s) may comprise: VH-CHI-flexible linker-VH-CHI-Fc region chain;

10 or VH-CHI-VH-CHI-Fc region chain. The multivalent antibody herein preferably further comprises at least two (and preferably four) light chain variable domain polypeptides. The multivalent antibody herein may, for instance, comprise from about two to about eight light chain variable domain polypeptides. The light chain variable domain polypeptides contemplated here comprise a light chain variable domain and, optionally, further

15 comprise a CL domain.

#### *Other Amino Acid Sequence Modifications*

Amino acid sequence modification(s) of the anti-Cln101 antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of the

20 anti-Cln101 antibody are prepared by introducing appropriate nucleotide changes into the anti-Cln101 antibody nucleic acid, or by peptide synthesis.

Such modifications include, for example, deletions from, and/or insertions into, and/or substitutions of, residues within the amino acid sequences of the anti-Cln101 antibody. Any combination of deletion, insertion, and substitution is made to arrive at the

25 final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the anti-Cln101 antibody, such as changing the number or position of glycosylation sites.

A useful method for identification of certain residues or regions of the anti-Cln101 antibody that are preferred locations for mutagenesis is called "alanine scanning

30 mutagenesis" as described by Cunningham and Wells in Science, 244:1081-1085 (1989). Here, a residue or group of target residues within the anti-Cln101 antibody are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or

negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with Cln101 antigen.

Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at a target codon or region and the expressed anti-Cln101 antibody variants are screened for the desired activity.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an anti-Cln101 antibody with an N-terminal methionyl residue or the antibody fused to a cytotoxic polypeptide. Other insertional variants of the anti-Cln101 antibody molecule include the fusion to the N- or C-terminus of the anti-Cln101 antibody to an enzyme (e.g. for ADEPT) or a fusion to a polypeptide which increases the serum half-life of the antibody.

Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the anti-Cln101 antibody molecule replaced by a different residue. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are shown in Table I under the heading of "preferred substitutions". If such substitutions result in a change in biological activity, then more substantial changes, denominated "exemplary substitutions" in Table 1, or as further described below in reference to amino acid classes, may be introduced and the products screened for a desired characteristic.

TABLE I Amino Acid Substitutions

Original	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val; leu; ile	Val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; asp, lys; arg	gln
Asp (D)	glu; asn	glu
Cys (C)	ser; ala	ser
Gln (Q)	asn; glu	asn

Glu (E)	asp; gln	asp
Gly (G)	ala	ala
His (H)	asn; gln; lys; arg	arg
Ile (I)	leu; val; met; ala; phe;	leu
Leu (L)	norleucine; ile; val; met; ala;	ile
Lys (K)	arg; gin; asn	arg
Met (M)	leu; phe; ile	leu
Phe (F)	leu; val; ile; ala; tyr	tyr
Pro (P)	ala	ala
Ser (S)	thr	thr
Thr (T)	ser	ser
Trp (W)	tyr; phe	tyr
Tyr (Y)	trp; phe; thr; ser	Phe
Val (V)	ile; leu; met; phe; ala;	leu

Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

(1) hydrophobic: norleucine, met, ala, val, leu, ile; (2) neutral hydrophilic: cys, ser, thr; (3) acidic: asp, glu; (4) basic: asn, gin, his, lys, arg; (5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Any cysteine residue not involved in maintaining the proper conformation of the anti-Cln101 antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.

Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).

A particularly preferred type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants involves affinity maturation using phage display. Briefly, several hypervariable region sites (e.g. 6-7 sites) are mutated to generate all possible amino acid substitutions at each site. The antibody

variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g. binding affinity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or additionally, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and human Cln101. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.

Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. By altering is meant deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody. Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).

Nucleic acid molecules encoding amino acid sequence variants of the anti-Cln101 antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring

amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared nucleic acid molecule encoding a variant or a non-variant version of the anti-Cln101 antibody.

5           It may be desirable to modify the antibody of the invention with respect to effector function, e.g. so as to enhance antigen-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) of the antibody. This may be achieved by introducing one or more amino acid substitutions in an Fc region of the antibody. Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region,  
10       thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may  
15       also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al. Anti-Cancer Drug Design 3:219-230 (1989).

          To increase the serum half life of the antibody, one may incorporate a salvage  
20       receptor binding epitope into the antibody (especially an antibody fragment) as described in U.S. Patent 5,739,277, for example. As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of the antibody.

#### Screening for Antibodies with the Desired Properties

          Techniques for generating antibodies have been described above. One may further  
25       select antibodies with certain biological characteristics, as desired.

          The growth inhibitory effects of an anti-Cln101 antibody of the invention may be assessed by methods known in the art, e.g., using cells which express Cln101 either endogenously or following transfection with the Cln101 gene. For example, the tumor cell lines and Cln101-transfected cells provided in Example 1 below may be treated with  
30       an anti-Cln101 monoclonal antibody of the invention at various concentrations for a few days (e.g., 2-7) days and stained with crystal violet or MTT or analyzed by some other colorimetric assay. Another method of measuring proliferation would be by comparing

<sup>3</sup>H-thymidine uptake by the cells treated in the presence or absence an anti-Cln101 antibody of the invention. After antibody treatment, the cells are harvested and the amount of radioactivity incorporated into the DNA quantitated in a scintillation counter. Appropriated positive controls include treatment of a selected cell line with a growth inhibitory antibody known to inhibit growth of that cell line. Growth inhibition of tumor cells in vivo can be determined in various ways such as is described in the Experimental Examples section below. Preferably, the tumor cell is one that over-expresses Cln101. Preferably, the anti-Cln101 antibody will inhibit cell proliferation of a Cln101-expressing tumor cell in vitro or in vivo by about 25-100% compared to the untreated tumor cell, more preferably, by about 30-100%, and even more preferably by about 50-100% or 70-100%, at an antibody concentration of about 0.5 to 30 µg/ml. Growth inhibition can be measured at an antibody concentration of about 0.5 to 30 µg/ml or about 0.5 nM to 200nM in cell culture, where the growth inhibition is determined 1-10 days after exposure of the tumor cells to the antibody. The antibody is growth inhibitory in vivo if administration of the anti-Cln101 antibody at about 1µg/kg to about 100mg/kg body weight results in reduction in tumor size or tumor cell proliferation within about 5 days to 3 months from the first administration of the antibody, preferably within about 5 to 30 days.

To select for antibodies which induce cell death, loss of membrane integrity as indicated by, e.g., propidium iodide (PI), trypan blue or 7AAD uptake may be assessed relative to a control. A PI uptake assay can be performed in the absence of complement and immune effector cells. Cln101-expressing tumor cells are incubated with medium alone or medium containing of the appropriate monoclonal antibody at e.g., about 10µg/ml. The cells are incubated for a 3 day time period. Following each treatment, cells are washed and aliquoted into 35 mm strainer-capped 12 x 75 tubes (1ml per tube, 3 tubes per treatment group) for removal of cell clumps. Tubes then receive PI (10µg/ml). Samples may be analyzed using a FACSCAN<sup>TM</sup> flow cytometer and FACSCONVERT<sup>TM</sup> CellQuest software (Becton Dickinson). Those antibodies which induce statistically significant levels of cell death as determined by PI uptake may be selected as cell death-inducing antibodies.

To screen for antibodies which bind to an epitope on Cln101 bound by an antibody of interest, e.g., the Cln101 antibodies of this invention, a routine cross-blocking assay such as that describe in *Antibodies, A Laboratory Manual*, Cold Spring Harbor

Laboratory, Ed Harlow and David Lane (1988), can be performed. This assay can be used to determine if a test antibody binds the same site or epitope as an anti-Cln101 antibody of the invention. Alternatively, or additionally, epitope mapping can be performed by methods known in the art. For example, the antibody sequence can be mutagenized such as by alanine scanning, to identify contact residues. The mutant antibody is initially tested for binding with polyclonal antibody to ensure proper folding. In a different method, peptides corresponding to different regions of Cln101 can be used in competition assays with the test antibodies or with a test antibody and an antibody with a characterized or known epitope.

For example, a method to screen for antibodies that bind to an epitope which is bound by an antibody this invention may comprise combining an Cln101-containing sample with a test antibody and an antibody of this invention to form a mixture, the level of Cln101 antibody bound to Cln101 in the mixture is then determined and compared to the level of Cln101 antibody bound in the mixture to a control mixture, wherein the level of Cln101 antibody binding to Cln101 in the mixture as compared to the control is indicative of the test antibody's binding to an epitope that is bound by the anti-Cln101 antibody of this invention. The level of Cln101 antibody bound to Cln101 is determined by ELISA. The control may be a positive or negative control or both. For example, the control may be a mixture of Cln101, Cln101 antibody of this invention and an antibody known to bind the epitope bound by the Cln101 antibody of this invention. The anti-Cln101 antibody labeled with a label such as those disclosed herein. The Cln101 may be bound to a solid support, e.g., a tissue culture plate or to beads, e.g., sepharose beads.

#### Immunoconjugates

The invention also pertains to therapy with immunoconjugates comprising an antibody conjugated to an anti-cancer agent such as a cytotoxic agent or a growth inhibitory agent.

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Conjugates of an antibody and one or more small molecule toxins, such as a calicheamicin, maytansinoids, a trichothene, and CC1065, and the derivatives of these toxins that have toxin activity, are also contemplated herein.

*Maytansine and maytansinoids*

Preferably, an anti-Cln101 antibody (full length or fragments) of the invention is conjugated to one or more maytansinoid molecules.

Maytansinoids are mitototic inhibitors which act by inhibiting tubulin polymerization.

5 Maytansine was first isolated from the cast African shrub *Maytenus serrata* (U.S. Patent No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No. 4,151,042). Synthetic maytansinol and derivatives and analogues thereof are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814;  
10 4,294,757; 4,307,016; 4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821; 4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254; 4,362,663; and 4,371,533, the disclosures of which are hereby expressly incorporated by reference.

*Maytansinoid-Antibody Conjugates*

In an attempt to improve their therapeutic index, maytansine and maytansinoids  
15 have been conjugated to antibodies specifically binding to tumor cell antigens. Immunoconjugates containing maytansinoids and their therapeutic use are disclosed, for example, in U.S. Patent Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 B1, the disclosures of which are hereby expressly incorporated by reference. Liu et al., Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996) described immunoconjugates comprising a  
20 maytansinoid designated DMI linked to the monoclonal antibody C242 directed against human colorectal cancer. The conjugate was found to be highly cytotoxic towards cultured colon cancer cells, and showed antitumor activity in an in vivo tumor growth assay. Chari et al. Cancer Research 52:127-131 (1992) describe immunoconjugates in which a  
25 maytansinoid was conjugated via a disulfide linker to the murine antibody A7 binding to an antigen on human colon cancer cell lines, or to another murine monoclonal antibody TA.1 that binds the HER-2/neu oncogene. The cytotoxicity of the TA.1-maytansinoid conjugate was tested in vitro on the human breast cancer cell line SK-BR-3, which expresses  $3 \times 10^5$  HER-2 surface antigens per cell. The drug conjugate achieved a degree of cytotoxicity similar to the free maytansinoid drug, which could be increased by  
30 increasing the number of maytansinoid molecules per antibody molecule. The A7-maytansinoid conjugate showed low systemic cytotoxicity in mice.

*Anti-Cln101 antibody-Maytansinoid Conjugates (Immunoconjugates)*

Anti-Cln101 antibody-maytansinoid conjugates are prepared by chemically linking an anti-Cln101 antibody to a maytansinoid molecule without significantly diminishing the biological activity of either the antibody or the maytansinoid molecule. An average of 3-4  
5 maytansinoid molecules conjugated per antibody molecule has shown efficacy in enhancing cytotoxicity of target cells without negatively affecting the function or solubility of the antibody, although even one molecule of toxin/antibody would be expected to enhance cytotoxicity over the use of naked antibody. Maytansinoids are well known in the art and can be synthesized by known techniques or isolated from natural  
10 sources. Suitable maytansinoids are disclosed, for example, in U.S. Patent No. 5,208,020 and in the other patents and nonpatent publications referred to hereinabove. Preferred maytansinoids are maytansinol and maytansinol analogues modified in the aromatic ring or at other positions of the maytansinol molecule, such as various maytansinol esters.

There are many linking groups known in the art for making antibody-maytansinoid  
15 conjugates, including, for example, those disclosed in U.S. Patent No. 5,208,020 or EP Patent 0 425 235 B 1, and Chari et al. Cancer Research 52: 127-131 (1992). The linking groups include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups, or esterase labile groups, as disclosed in the above-identified patents, disulfide and thioether groups being preferred. Conjugates of the antibody and  
20 maytansinoid may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl (2-pyridyldithio) propionate (SPDP), succinimidyl- (N-maleimidomethyl) cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis-(p-azidobenzoyl)  
25 hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Particularly preferred coupling agents include N-succinimidyl (2-pyridyldithio) propionate (SPDP) (Carlsson et al., Biochem. J. 173:723-737 [1978]) and N-succinimidyl (2-pyridylthio)pentanoate (SPP) to  
30 provide for a disulfide linkage.

The linker may be attached to the maytansinoid molecule at various positions, depending on the type of the link. For example, an ester linkage may be formed by

reaction with a hydroxyl group using conventional coupling techniques. The reaction may occur at the C-3 position having a hydroxyl group, the C-14 position modified with hydroxymethyl, the C-15 position modified with a hydroxyl group, and the C-20 position having a hydroxyl group. Preferably, the linkage is formed at the C-3 position of  
5 maytansinol or a maytansinol analogue.

### *Calicheamicin*

Another immunoconjugate of interest comprises an anti-Cln101 antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar  
10 concentrations. For the preparation of conjugates of the calicheamicin family, see U.S. patents 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, 5,877,296 (all to American Cyanamid Company). Structural analogues of calicheamicin which may be used include, but are not limited to,  $\gamma_1^I$ ,  $\alpha_2^I$ ,  $\alpha_3^I$ , N-acetyl-  $\gamma_1^I$ , PSAG and  $\theta_1^I$ , (Hinman et al. Cancer Research 53: 3336 (1993), Lode et al. Cancer Research 58:  
15 2925-2928 (1998) and the aforementioned U.S. patents to American Cyanamid). Another anti-tumor drug that the antibody can be conjugated is QFA which is an antifolate. Both calicheamicin and QFA have intracellular sites of action and do not readily cross the plasma membrane. Therefore, cellular uptake of these agents through antibody mediated internalization greatly enhances their cytotoxic effects.

### 20 Other Cytotoxic Agents

Other antitumor agents that can be conjugated to the anti-Cln101 antibodies of the invention include BCNU, streptozocin, vincristine and 5-fluorouracil, the family of agents known collectively LL-E33288 complex described in U.S. patents 5,053,394, 5,770,710, as well as esperamicins (U.S. patent 5,877,296). Enzymatically active toxins and  
25 fragments thereof which can be used include diphtheria A chain, 15 nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolacca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcumin, croton, saponaria officinalis inhibitor, gelonin, mitogellin, restrictocin,  
30 phenomycin, enomycin and the tricothecenes. See, for example, WO 93/21232 published October 28, 1993. The present invention further contemplates an immunoconjugate

formed between an antibody and a compound with nucleolytic activity (e.g. a ribonuclease or a DNA endonuclease such as a deoxyribonuclease; DNase).

For selective destruction of the tumor, the antibody may comprise a highly radioactive atom. A variety of radioactive isotopes are available for the production of radioconjugated anti-Cln101 antibodies. Examples include  $\text{At}^{211}$ ,  $\text{I}^{131}$ ,  $\text{I}^{125}$ ,  $\text{In}^{111}$ ,  $\text{Y}^{90}$ ,  $\text{Re}^{186}$ ,  $\text{Re}^{188}$ ,  $\text{Sm}^{153}$ ,  $\text{Bi}^{212}$ ,  $\text{P}^{32}$ , and radioactive isotopes of Lu. When the conjugate is used for diagnosis, it may comprise a radioactive atom for scintigraphic studies, for example  $\text{Tc}^{99\text{M}}$  or  $\text{I}^{123}$ , or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

The radio- or other labels may be incorporated in the conjugate in known ways. For example, the peptide may be biosynthesized or may be synthesized by chemical amino acid synthesis using suitable amino acid precursors involving, for example, fluorine-19 in place of hydrogen. Labels such as  $\text{Tc}^{99\text{M}}$ ,  $\text{I}^{123}$ ,  $\text{In}^{111}$ ,  $\text{Re}^{186}$ ,  $\text{Re}^{188}$ , can be attached via a cysteine residue in the peptide. Yttrium-90 can be attached via a lysine residue. The IODOGEN method (Fraker et al (1978) Biochem. Biophys. Res. Commun. 80: 49-57 can be used to incorporate iodine "Monoclonal Antibodies in Immunoscintigraphy" (Chatal, CRC Press 1989) describes other methods in detail.

Conjugates of the antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl (2-pyridyldithio) propionate (SPDP), succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al. Science 238: 1098 (1987). Carbon labeled 1-isothiocyanatobenzyl methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO 94/11026. The linker may be a "cleavable linker" facilitating release of the cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker

(Chari et al. Cancer Research 52: 127-131 (1992); U.S. Patent No. 5,208,020) may be used.

Alternatively, a fusion protein comprising the anti-Cln101 antibody and cytotoxic agent may be made, e.g. by recombinant techniques or peptide synthesis. The length of DNA may comprise respective regions encoding the two portions of the conjugate either  
5 adjacent one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.

In addition, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pre-targeting wherein the antibody-receptor conjugate is administered  
10 to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g. avidin) which is conjugated to a cytotoxic agent (e.g. a radionucleotide).

#### Antibody Dependent Enzyme Mediated Prodrug Therapy (ADEPT)

The antibodies of the present invention may also be used in ADEPT by  
15 conjugating the antibody to a prodrug-activating enzyme which converts a prodrug (e.g. a peptidyl chemotherapeutic agent, see W081/01145) to an active anti-cancer drug. See, for example, WO 88/07378 and U.S. Patent No. 4,975,278.

The enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such a way so as to covert it into its more active,  
20 cytotoxic form. Enzymes that are useful in the method of this invention include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin,  
25 carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as O-galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs; P-lactamase useful for converting drugs derivatized with P-  
30 lactams into free drugs; and penicillin amidases, such as penicillin V amidase or penicillin G amidase, useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. Alternatively,

antibodies with enzymatic activity, also known in the art as "abzymes", can be used to convert the prodrugs of the invention into free active drugs (see, e.g., Massey, Nature 328: 457-458 (1987)). Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a tumor cell population. The enzymes of this invention can be covalently bound to the anti-Cln101 antibodies by techniques well known in the art such as the use of the heterobifunctional crosslinking reagents discussed above.

Alternatively, fusion proteins comprising at least the antigen binding region of an antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger et al., Nature, 312: 604-608 (1984)).

#### Other Antibody Modifications

Other modifications of the antibody are contemplated herein. For example, the antibody may be linked to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol. The antibody also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly(methylmethacrylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A., Ed., (1980).

The anti-Cln101 antibodies disclosed herein may also be formulated as immunoliposomes. A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82:3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77:4030 (1980); U.S. Pat. Nos. 4,485,045 and 4,544,545; and W097/38731 published October 23, 1997. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556. Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol

and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al. J. Biol. Chem. 257: 286-288 (1982) via a disulfide interchange reaction. A chemotherapeutic agent is optionally contained within the liposome. See Gabizon et al. J. National Cancer Inst. 81(19)1484 (1989).

#### Vectors, Host Cells, and Recombinant Methods

The invention also provides isolated nucleic acid molecule encoding the humanized anti-Cln101 antibody, vectors and host cells comprising the nucleic acid, and recombinant techniques for the production of the antibody. For recombinant production of the antibody, the nucleic acid molecule encoding it is isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or inserted into a vector in operable linkage with a promoter for expression. DNA encoding the monoclonal antibody is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to nucleic acid molecules encoding the heavy and light chains of the antibody). Many vectors are available. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

#### 20 *Signal Sequence Component*

The anti-Cln101 antibody of this invention may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. The heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the native anti-Cln101 antibody signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the native signal sequence may be substituted by, e.g., the yeast invertase leader, oc factor leader (including *Saccharomyces* and *Kluyveromyces* cc-factor leaders), or acid phosphatase

leader, the *C. albicans* glucoamylase leader, or the signal described in WO 90/13646. In mammalian cell expression, mammalian signal sequences as well as viral secretory leaders, for example, the herpes simplex gD signal, are available. The DNA for such precursor region is ligated in reading frame to DNA encoding the anti-Cln101 antibody.

5        *Origin of Replication*

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

10  
15

*Selection Gene Component*

Expression and cloning vectors may contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*. One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene produce a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin, mycophenolic acid and hygromycin.

20  
25

Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the anti-Cln101 antibody nucleic acid, such as DHFR, thymidine kinase, metallothionein-I and -II, preferably primate metallothionein genes, adenosine deaminase, ornithine decarboxylase, etc. For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive

30

antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity (e.g., ATCC CRL-9096).

Alternatively, host cells (particularly wild-type hosts that contain endogenous  
5 DHFR) transformed or co-transformed with DNA sequences encoding anti-Cln101 antibody, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3'-phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S. Patent No. 4,965,199.

10 A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 (Stinchcomb et al., *Nature*, 282:39 (1979)). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4 Jones, *Genetics*, 85:12 (1977). The presence of the *trp1* lesion in the yeast host cell genome then provides an effective environment for  
15 detecting transformation by growth in the absence of tryptophan. Similarly, *Leu2*-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the *Leu2* gene.

In addition, vectors derived from the 1.6 pm circular plasmid pKDI can be used for transformation of *Kluyveromyces* yeasts. Alternatively, an expression system for large-  
20 scale production of recombinant calf chymosin was reported for *K. lactis*. Van den Berg, *Bio/Technology*, 8:135 (1990). Stable multi-copy expression vectors for secretion of mature recombinant human serum albumin by industrial strains of *Kluyveromyces* have also been disclosed. Fleer et al., *Bio/Technology*, 9:968-975 (1991).

#### *Promoter Component*

25 Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the anti-Cln101 antibody nucleic acid. Promoters suitable for use with prokaryotic hosts include the *phoA* promoter, *P*-lactamase and lactose promoter systems, alkaline phosphatase promoter, a tryptophan (*trp*) promoter system, and hybrid promoters such as the *tac* promoter. However, other known bacterial  
30 promoters are suitable. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the anti-Cln101 antibody.

Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CNCAAT region where N may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into eukaryotic expression vectors. Examples of suitable promoter sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, such as enolase, glyceraldehyde phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. Yeast enhancers also are advantageously used with yeast promoters.

Anti-Cln101 antibody transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, from heat-shock promoters, provided such promoters are compatible with the host cell systems.

The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. Patent No. 4,419,446. A modification of this system is described in U.S. Patent No. 4,601,978. See also Reyes et

al., Nature 297:598-601 (1982) on expression of human P-interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus. Alternatively, the Rous Sarcoma Virus long terminal repeat can be used as the promoter.

#### *Enhancer Element Component*

5 Transcription of a DNA encoding the anti-Cln101 antibody of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the  
10 replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, Nature 297:17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the anti-Cln101 antibody-encoding sequence, but is preferably located at a site 5' from the  
15 promoter.

#### *Transcription Termination Component*

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such  
20 sequences are commonly available from the 5' and, occasionally 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding anti-Cln101 antibody. One useful transcription termination component is the bovine growth hormone polyadenylation region. See WO 94/11026 and the expression  
25 vector disclosed therein.

#### *Selection and Transformation of Host Cells*

Suitable host cells for cloning or expressing the DNA in the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for  
30 example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia

marcescans, and Shigella, as well as Bacilli such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. One preferred *E. coli* cloning host is *E. coli* 294 (ATCC 31,446), although other strains such as *E. coli* B, *E. coli* X1776 (ATCC 31,537),  
5 and *E. coli* W31 10 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting.

Full length antibody, antibody fragments, and antibody fusion proteins can be produced in bacteria, in particular when glycosylation and Fc effector function are not needed, such as when the therapeutic antibody is conjugated to a cytotoxic agent (e.g., a  
10 toxin) and the immunoconjugate by itself shows effectiveness in tumor cell destruction. Full length antibodies have greater half life in circulation. Production in *E. coli* is faster and more cost efficient. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. 5,648,237 (Carter et. al.), U.S. 5,789,199 (Joly et al.), and U.S. 5,840,523 (Simmons et al.) which describes translation initiation region (TIR) and signal  
15 sequences for optimizing expression and secretion, these patents incorporated herein by reference. After expression, the antibody is isolated from the *E. coli* cell paste in a soluble fraction and can be purified through, e.g., a protein A or G column depending on the isotype. Final purification can be carried out similar to the process for purifying antibody expressed e.g., in CHO cells.

20 In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for anti-Cln101 antibody-encoding vectors. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as *Schizosaccharomyces pombe*;  
25 *Kluyveromyces* hosts such as, e.g., *K. lactis*, *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilum* (ATCC 36,906), *K. thermotolerans*, and *K. marxianus*; *Yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa*; *Schwanniomyces* such as *Schwanniomyces occidentalis*; and  
30 filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium*, and *Aspergillus* hosts such as *A. nidulans* and *A. niger*.

Suitable host cells for the expression of glycosylated anti-Cln101 antibody are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells.

Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, *Arabidopsis* and tobacco can also be utilized as hosts. Cloning and expression vectors useful in the production of proteins in plant cell culture are known to those of skill in the art. See e.g. Hiatt et al., *Nature* (1989) 342: 76-78, Owen et al. (1992) *Bio/Technology* 10: 790-794, Artsaenko et al. (1995) *The Plant J* 8: 745-750, and Fecker et al. (1996) *Plant Mol Biol* 32: 979-986.

However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., *J. Gen Virol.* 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., *Proc. Natl. Acad. Sci. USA* 77:4216 (1980)); mouse sertoli cells (TM4, Mather, *Biol. Reprod.* 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, 1413 8065); mouse mammary tumor (MMT 060562, ATCC CCL5 1); TRI cells (Mather et al., *Annals N. Y Acad. Sci.* 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

Host cells are transformed with the above-described expression or cloning vectors for anti-Cln101 antibody production and cultured in conventional nutrient media modified

as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

#### *Culturing Host Cells*

The host cells used to produce the anti-Cln101 antibody of this invention may be  
5 cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma),  
Minimal Essential Medium (MEM)(Sigma), RPMI-1640 (Sigma), and Dulbecco's  
Modified Eagle's Medium (DMEM)(Sigma) are suitable for culturing the host cells. In  
addition, any of the media described in Ham et al., Meth. Enz. 58:44 (1979), Barnes et al.,  
Anal. Biochem. 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762;  
10 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Patent Re. 30,985 may be  
used as culture media for the host cells. Any of these media may be supplemented as  
necessary with hormones and/or other growth factors (such as insulin, transferrin, or  
epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and  
phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine),  
15 antibiotics (such as GENTAMYCIN<sup>TM</sup> drug), trace elements (defined as inorganic  
compounds usually present at final concentrations in the micromolar range), and glucose  
or an equivalent energy source. Any other necessary supplements may also be included at  
appropriate concentrations that would be known to those skilled in the art. The culture  
conditions, such as temperature, pH, and the like, are those previously used with the host  
20 cell selected for expression, and will be apparent to the ordinarily skilled artisan.

#### *Purification of anti-Cln101 antibody*

When using recombinant techniques, the antibody can be produced intracellularly,  
in the periplasmic space, or directly secreted into the medium. If the antibody is produced  
intracellularly, as a first step, the particulate debris, either host cells or lysed fragments,  
25 are removed, for example, by centrifugation or ultrafiltration. Carter et al.,  
Bio/Technology 10: 163-167 (1992) describe a procedure for isolating antibodies which  
are secreted to the periplasmic space of E coli. Briefly, cell paste is thawed in the presence  
of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about  
30 min. Cell debris can be removed by centrifugation. Where the antibody is secreted into  
30 the medium, supernatants from such expression systems are generally first concentrated  
using a commercially available protein concentration filter, for example, an Amicon or

Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.

The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human  $\gamma 1$ ,  $\gamma 2$ , or  $\gamma 4$  heavy chains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and for human  $\gamma 3$  (Guss et al., EMBO J. 5:15671575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a CH3 domain, the Bakerbond ABX<sup>TM</sup> resin (J. T. Baker, Phillipsburg, NJ) is useful for purification. Other techniques for protein purification such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE<sup>TM</sup> chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SIDS-PAGE, and ammonium sulfate precipitation are also available depending on the antibody to be recovered.

Following any preliminary purification step(s), the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5 - 4.5, preferably performed at low salt concentrations (e.g., from about 0-0.25M salt).

#### Pharmaceutical Formulations

Pharmaceutical formulations of the antibodies used in accordance with the present invention are prepared for storage by mixing an antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and

include buffers such as acetate, Tris, phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol, and m-cresol);  
5 low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or  
10 dextrans; chelating agents such as EDTA; tonicifiers such as trehalose and sodium chloride; sugars such as sucrose, mannitol, trehalose or sorbitol; surfactant such as polysorbate; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as TWEEN<sup>TM</sup>, PLURONICS<sup>TM</sup> or polyethylene glycol (PEG). The antibody preferably comprises the antibody at a  
15 concentration of between 5-200 mg/ml, preferably between 10-100 mg/ml.

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, in addition to the anti-Cln101 antibody which internalizes, it may be desirable to include in the one formulation,  
20 an additional antibody, e.g. a second anti-Cln101 antibody which binds a different epitope on Cln101, or an antibody to some other target such as a growth factor that affects the growth of the particular cancer. Alternatively, or additionally, the composition may further comprise a chemotherapeutic agent, cytotoxic agent, cytokine, growth inhibitory agent, anti-hormonal agent, and/or cardioprotectant. Such molecules are suitably present in  
25 combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes,  
30 albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for  
5 example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-) hydroxybutyric acid.

10 The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

#### Methods and Treatment Using Anti-Cln101 Antibodies

According to the present invention, the anti-Cln101 antibody that binds to Cln101 in vivo or internalizes upon binding Cln101 on a cell surface is used to treat a subject in  
15 need thereof having a cancer characterized by Cln101-expressing cancer cells, in particular, ovarian, pancreatic, lung or breast cancer, such as ovarian serous adenocarcinoma or breast infiltrating ductal carcinoma cancer, and associated metastases.

The cancer will generally comprise Cln101-expressing cells, such that the anti-Cln101 antibody is able to bind thereto. While the cancer may be characterized by  
20 overexpression of the Cln101 molecule, the present application further provides a method for treating cancer which is not considered to be a Cln101-overexpressing cancer.

This invention also relates to methods for detecting cells which overexpress Cln101 and to diagnostic kits useful in detecting cells expressing Cln101 or in detecting Cln101 in serum from a patient or other bodily fluids. The methods may comprise  
25 combining a cell-containing test sample with an antibody of this invention, assaying the test sample for antibody binding to cells in the test sample and comparing the level of antibody binding in the test sample to the level of antibody binding in a control sample of cells. A suitable control is, e.g., a sample of normal cells of the same type as the test sample or a cell sample known to be free of Cln101 overexpressing cells. A level of  
30 Cln101 binding higher than that of such a control sample would be indicative of the test sample containing cells that overexpress Cln101. Alternatively the control may be a sample of cells known to contain cells that overexpress Cln101. In such a case, a level of

Cln101 antibody binding in the test sample that is similar to, or in excess of, that of the control sample would be indicative of the test sample containing cells that overexpress Cln101.

Cln101 overexpression may be detected with a various diagnostic assays. For example, over expression of Cln101 may be assayed by immunohistochemistry (IHC). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded an Cln101 protein staining intensity criteria as follows.

Score 0 no staining is observed or membrane staining is observed in less than 10% of tumor cells.

Score 1+ a faint/barely perceptible membrane staining is detected in more than 10% of the tumor cells. The cells are only stained in part of their membrane.

Score 2+ a weak to moderate complete membrane staining is observed in more than 10% of the tumor cells.

Score 3+ a moderate to strong complete membrane staining is observed in more than 10% of the tumor cells.

Those tumors with 0 or 1+ scores for Cln101 expression may be characterized as not overexpressing Cln101, whereas those tumors with 2+ or 3+ scores may be characterized as overexpressing Cln101.

Alternatively, or additionally, FISH assays such as the INFORM<sup>TM</sup> (sold by Ventana, Arizona) or PATHVISION<sup>TM</sup> (VySiS, Illinois) may be carried out on formalin-fixed, paraffin-embedded tumor tissue to determine the extent (if any) of Cln101 overexpression in the tumor. Cln101 overexpression or amplification may be evaluated using an in vivo diagnostic assay, e.g. by administering a molecule (such as an antibody of this invention) which binds Cln101 and which is labeled with a detectable label (e.g. a radioactive isotope or a fluorescent label) and externally scanning the patient for localization of the label.

A sample suspected of containing cells expressing or overexpressing Cln101 is combined with the antibodies of this invention under conditions suitable for the specific binding of the antibodies to Cln101. Binding and/or internalizing the Cln101 antibodies of this invention is indicative of the cells expressing Cln101. The level of binding may be determined and compared to a suitable control, wherein an elevated level of bound Cln101 as compared to the control is indicative of Cln101 overexpression. The sample suspected

of containing cells overexpressing Cln101 may be a cancer cell sample, particularly a sample of an ovarian cancer, e.g. ovarian serous adenocarcinoma, or a breast cancer, e.g., a breast infiltrating ductal carcinoma. A serum sample from a subject may also be assayed for levels of Cln101 by combining a serum sample from a subject with an Cln101

5 antibody of this invention, determining the level of Cln101 bound to the antibody and comparing the level to a control, wherein an elevated level of Cln101 in the serum of the patient as compared to a control is indicative of overexpression of Cln101 by cells in the patient. The subject may have a cancer such as e.g., an ovarian cancer, e.g. ovarian serous adenocarcinoma, or a breast cancer, e.g., a breast infiltrating ductal carcinoma.

10       Currently, depending on the stage of the cancer, ovarian, pancreatic, lung or breast cancer treatment involves one or a combination of the following therapies: surgery to remove the cancerous tissue, radiation therapy, androgen deprivation (e.g., hormonal therapy), and chemotherapy. Anti-Cln101 antibody therapy may be especially desirable in elderly patients who do not tolerate the toxicity and side effects of chemotherapy well, in  
15 metastatic disease where radiation therapy has limited usefulness, and for the management of prostatic carcinoma that is resistant to androgen deprivation treatment. The tumor targeting and internalizing anti-Cln101 antibodies of the invention are useful to alleviate Cln101-expressing cancers, e.g., ovarian, pancreatic, lung or breast cancers upon initial diagnosis of the disease or during relapse. For therapeutic applications, the anti-Cln101  
20 antibody can be used alone, or in combination therapy with, e.g., hormones, antiangiogens, or radiolabelled compounds, or with surgery, cryotherapy, and/or radiotherapy, notably for ovarian, pancreatic, lung or breast cancers, also particularly where shed cells cannot be reached. Anti-Cln101 antibody treatment can be administered in conjunction with other forms of conventional therapy, either consecutively with, pre- or  
25 post-conventional therapy, Chemotherapeutic drugs such as Taxotere® (docetaxel), Taxol® (paclitaxel), estramustine and mitoxantrone are used in treating metastatic and hormone refractory ovarian, pancreatic, lung or breast cancer, in particular, in good risk patients. In the present method of the invention for treating or alleviating cancer, in particular, androgen independent and/or metastatic ovarian, pancreatic, lung or breast  
30 cancer, the cancer patient can be administered anti-Cln101 antibody in conjunction with treatment with the one or more of the preceding chemotherapeutic agents. In particular, combination therapy with paclitaxel and modified derivatives (see, e.g., EP0600517) is

contemplated. The anti-Cln101 antibody will be administered with a therapeutically effective dose of the chemotherapeutic agent. The anti-Cln101 antibody may also be administered in conjunction with chemotherapy to enhance the activity and efficacy of the chemotherapeutic agent, e.g., paclitaxel. The Physicians' Desk Reference (PDR) discloses dosages of these agents that have been used in treatment of various cancers. The dosing regimen and dosages of these aforementioned chemotherapeutic drugs that are therapeutically effective will depend on the particular cancer being treated, the extent of the disease and other factors familiar to the physician of skill in the art and can be determined by the physician.

Particularly, an immunoconjugate comprising the anti-Cln101 antibody conjugated with a cytotoxic agent may be administered to the patient. Preferably, the immunoconjugate bound to the Cln101 protein is internalized by the cell, resulting in increased therapeutic efficacy of the immunoconjugate in killing the cancer cell to which it binds. Preferably, the cytotoxic agent targets or interferes with the nucleic acid in the cancer cell. Examples of such cytotoxic agents are described above and include maytansin, maytansinoids, saporin, gelonin, ricin, calicheamicin, ribonucleases and DNA endonucleases.

The anti-Cln101 antibodies or immunoconjugates are administered to a human patient, in accord with known methods, such as intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. The antibodies or immunoconjugates may be injected directly into the tumor mass. Intravenous or subcutaneous administration of the antibody is preferred. Other therapeutic regimens may be combined with the administration of the anti-Cln101 antibody.

The combined administration includes co-administration, using separate formulations or a single pharmaceutical formulation, and consecutive administration in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities. Preferably such combined therapy results in a synergistic therapeutic effect.

It may also be desirable to combine administration of the anti-Cln101 antibody or antibodies, with administration of an antibody directed against another tumor antigen

associated with the particular cancer. As such, this invention is also directed to an antibody "cocktail" comprising one or more antibodies of this invention and at least one other antibody which binds another tumor antigen associated with the Cln101-expressing tumor cells. The cocktail may also comprise antibodies that are directed to other epitopes of Cln101. Preferably the other antibodies do not interfere with the binding and or  
5 internalization of the antibodies of this invention.

The antibody therapeutic treatment method of the present invention may involve the combined administration of an anti-Cln101 antibody (or antibodies) and one or more chemotherapeutic agents or growth inhibitory agents, including co-administration of  
10 cocktails of different chemotherapeutic agents. Chemotherapeutic agents include, e.g., estramustine phosphate, prednimustine, cisplatin, 5-fluorouracil, melphalan, cyclophosphamide, hydroxyurea and hydroxyureataxanes (such as paclitaxel and doxetaxel) and/or anthracycline antibiotics. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as  
15 determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service Ed., M.C. Perry, Williams & Wilkins, Baltimore, MD (1992).

The antibody may be combined with an anti-hormonal compound; e.g., an anti-estrogen compound such as tamoxifen; an anti-progesterone such as onapristone (see, EP  
20 616 812); or an anti-androgen such as flutamide, in dosages known for such molecules. Where the cancer to be treated is androgen independent cancer, the patient may previously have been subjected to anti-androgen therapy and, after the cancer becomes androgen independent, the anti-Cln101 antibody (and optionally other agents as described herein) may be administered to the patient.

Sometimes, it may be beneficial to also co-administer a cardioprotectant (to  
25 prevent or reduce myocardial dysfunction associated with the therapy) or one or more cytokines to the patient. In addition to the above therapeutic regimes, the patient may be subjected to surgical removal of cancer cells and/or radiation therapy, before, simultaneously with, or post antibody therapy. Suitable dosages for any of the above co-  
30 administered agents are those presently used and may be lowered due to the combined action (synergy) of the agent and anti-Cln101 antibody.

For the prevention or treatment of disease, the dosage and mode of administration will be chosen by the physician according to known criteria. The appropriate dosage of antibody will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive or  
5 therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Preferably, the antibody is administered by intravenous infusion or by subcutaneous injections. Depending on the type and severity of the disease, about 1 pg/kg to about 50 mg/kg body  
10 weight (e.g. about 0.1- 15 mg/kg/dose) of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A dosing regimen can comprise administering an initial loading dose of about 4 mg/kg, followed by a weekly maintenance dose of about 2 mg/kg of the anti-Cln101 antibody. However, other dosage regimens may be useful. A  
15 typical daily dosage might range from about 1 pg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. The progress of this therapy can be readily monitored by conventional methods and assays and based on criteria known to the physician or other  
20 persons of skill in the art.

Aside from administration of the antibody protein to the patient, the present application contemplates administration of the antibody by gene therapy. Such administration of a nucleic acid molecule encoding the antibody is encompassed by the expression "administering a therapeutically effective amount of an antibody". See, for  
25 example, WO 96/07321 published March 14, 1996 concerning the use of gene therapy to generate intracellular antibodies.

There are two major approaches to introducing the nucleic acid molecule (optionally contained in a vector) into the patient's cells; in vivo and ex vivo. For in vivo delivery the nucleic acid molecule is injected directly into the patient, usually at the site  
30 where the antibody is required. For ex vivo treatment, the patient's cells are removed, the nucleic acid molecule is introduced into these isolated cells and the modified cells are administered to the patient either directly or, for example, encapsulated within porous

membranes which are implanted into the patient (see, e.g. U.S. Patent Nos. 4,892,538 and 5,283,187). There are a variety of techniques available for introducing nucleic acid molecules into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells in vitro, or in vivo in the cells of the intended host.

- 5 Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. A commonly used vector for ex vivo delivery of the gene is a retroviral vector.

- 10 The currently preferred in vivo nucleic acid molecule transfer techniques include transfection with viral vectors (such as adenovirus, Herpes simplex I virus, or adeno-associated virus) and lipid-based systems (useful lipids for lipid-mediated transfer of the gene are DOTMA, DOPE and DC-Chol, for example). For review of the currently known gene marking and gene therapy protocols see Anderson et al., Science 256:808-813 (1992). See also WO 93/25673 and the references cited therein.

15 Articles of Manufacture and Kits

- The invention also relates to an article of manufacture containing materials useful for the detection for Cln101 overexpressing cells and/or the treatment of Cln101 expressing cancer, in particular prostate or ovarian cancer. The article of manufacture comprises a container and a composition contained therein comprising an antibody of this invention. The composition may further comprise a carrier. The article of manufacture may also comprise a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for detecting Cln101 expressing cells and/or treating a cancer condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an anti-Cln101 antibody of the invention. The label or package insert indicates that the composition is used for detecting Cln101 expressing cells and/or for treating prostate or ovarian cancer, or more specifically ovarian serous adenocarcinoma, breast infiltrating ductal carcinoma, prostate adenocarcinoma, renal cell carcinomas, colorectal adenocarcinomas, lung adenocarcinomas, lung squamous cell carcinomas, and pleural mesothelioma, in a patient in need thereof. The breast cancer
- 20
- 25
- 30

may be HER-2 negative or positive breast cancer. The cancers encompass metastatic cancers of any of the preceding, e.g., prostate or ovarian cancer metastases. The label or package insert may further comprise instructions for administering the antibody composition to a cancer patient. Additionally, the article of manufacture may further  
5 comprise a second container comprising a substance which detects the antibody of this invention, e.g., a second antibody which binds to the antibodies of this invention. The substance may be labeled with a detectable label such as those disclosed herein. The second container may contain e.g., a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWTI), phosphate-buffered saline, Ringer's solution and  
10 dextrose solution. The article of manufacture may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Kits are also provided that are useful for various purposes, e.g., for Cln101 cell killing assays, for purification or immunoprecipitation of Cln101 from cells or for  
15 detecting the presence of Cln101 in a serum sample or other bodily fluids or detecting the presence of Cln101-expressing cells in a cell sample.. For isolation and purification of Cln101, the kit can contain an anti-Cln101 antibody coupled to a solid support, e.g., a tissue culture plate or beads (e.g., sepharose beads). Kits can be provided which contain the antibodies for detection and quantitation of Cln101 in vitro, e.g. in an ELISA or a  
20 Western blot. As with the article of manufacture, the kit comprises a container and a composition contained therein comprising an antibody of this invention. The kit may further comprise a label or package insert on or associated with the container. The kits may comprise additional components, e.g., diluents and buffers, substances which bind to the antibodies of this invention, e.g., a second antibody which may comprise a label such  
25 as those disclosed herein, e.g., a radiolabel, fluorescent label, or enzyme, or the kit may also comprise control antibodies. The additional components may be within separate containers within the kit. The label or package insert may provide a description of the composition as well as instructions for the intended in vitro or diagnostic use.

## EXAMPLES

**Example 1: Production and Isolation of Monoclonal Antibody Producing Hybridomas**

The following MAb/hybridomas of the present invention are described below:

- 5 Cln101.A1.1, Cln101.A3.1, Cln101.A6.1, Cln101.A7.1, Cln101.A8.1, Cln101.A9.1,  
Cln101.A10.1, Cln101.A11.1, Cln101.A15.1, Cln101.A16, Cln101.A17.1, Cln101.A18.1,  
Cln101.A23.1, Cln101.A26.1, Cln101.A28.1, Cln101.A35.1, Cln101.A37.1,  
Cln101.A38.1, Cln101.A41.1, Cln101.A42.1, Cln101.A46.1, Cln101.A47.1, Cln101.C3,  
Cln101.C6, Cln101.C12, Cln101.C17, Cln101.C18, Cln101.C25, Cln101.C36,  
10 Cln101.C43 and Cln101.C47.

If the MAb has been cloned, it will get the nomenclature "X.1," e.g., the first clone of A2 will be referred to as A2.1, the second clone of A2 will be referred to as A2.2, etc. For the purposes of this invention, a reference to MAb A2 will include all clones, e.g., A2.1, A2.2, etc.

15 Immunogens and Antigens (Recombinant Proteins, HA & His Tags & Transfected Cells)

For immunization of mice and production of MAbs, two Cln101 recombinant proteins were generated. The first was a bacterial (*E. coli*) expressed soluble Cln101 recombinant protein.

- 20 MASRSMRLLLLLSCLAKTGVLGDIIMRPSCAPGWFYHKSNCYGYFRKLRNWSDAE  
LECQSYGNGAHLASILSLKEASTIAEYISGYQRSQPIWIGLHDPQKRQQWQWIDG  
AMYLYRSWSGKSMGGNKHCAEMSSNNNFLTWSSNECNKRQHFLCKYRP, SEQ  
ID NO:1.

- 25 A second Cln101 construct was cloned with a histidine tag immediately downstream of codon Ser161. For production of the C-series of MAbs this protein was cloned into a standard expression vector and expressed in mammalian cells using standard technology known to those of skill in the art.

- 30 MLQNSAVLLVLVISASATHEAEQDIIMRPSCAPGWFYHKSNCYGYFRKLRNWSDA  
ELECQSYGNGAHLASILSLKEASTIAEYISGYQRSQPIWIGLHDPQKRQQWQWID  
GAMYLYRSWSGKSMGGNKHCAEMSSNNNFLTWSSNECNKRQHFLCKYRPASHHHH  
HHHHHH, SEQ ID NO:2.

Immunizations

For generation of the A series MAbs mice were immunized with bacterial expressed soluble Cln101 recombinant protein, SEQ ID NO:1. Groups of 8 BALB/c mice were immunized intradermally in both rear footpads. All injections were 25 uL per foot. The first injection (day 1) of 10 ug of antigen per mouse was in Dulbecco's phosphate buffered saline (DPBS) mixed in equal volume to volume ratio with Titermax gold  
5 adjuvant (Sigma, Saint Louis, MS). Subsequent injections of 10 ug of antigen per mouse occurred on days 5, 9, 12, 16, 19, 23, 26, 29, 30 and consisted of antigen in 20 uL of DPBS plus 5uL of Adju-phos adjuvant (Accurate Chemical & Scientific Corp., Westbury, NY) per mouse. The final boost injection on day 33 consisted of antigen diluted in DPBS  
10 alone. Fusion occurred on Day 37.

For generation of the C-series MAbs mice were immunized as above with soluble mammalian expressed Cln101 recombinant protein, SEQ ID NO:2.

#### Hybridoma Fusions

Mice were sacrificed at the completion of the immunization protocol and draining  
15 lymph node (popliteal) tissue was collected by sterile dissection. Lymph node cells were dispersed by pressing through a sterile sieve into DMEM and removing T-cells via anti-CD90 (Thy1.2) coated magnetic beads (Miltenyl Biotech, Baraisch-Gladbach, Germany).

These primary B-cell enriched lymph node cells were then immortalized by electro-cell fusion (BTX, San Diego, CA) with the continuous myeloma cell line  
20 P3x63Ag8.653 (Kearney, J.F. et al., J. Immunology 123: 1548-1550, 1979). Successfully fused cells were selected by culturing in standard Hypoxanthine, Azaserine (HA) (Sigma) containing selection medium (DMEM/10% FBS). These fusion cultures were immediately distributed, 10 million cells per plate, into wells of 96 well culture plates. Distributing the culture in 96 well culture plates, immediately following fusion, facilitated selection of a  
25 larger diversity of hybridoma clones producing single, specific antibodies. Supernatants from wells were screened by ELISA, for reactivity against Cln101 protein.

Monoclonal cultures, consisting of the genetically uniform progeny from single cells, were established after the screening procedure above, by sorting of single viable cells into wells of two 96 well plates, using flow cytometry (Coulter Elite). The resulting  
30 murine B-cell hybridoma cultures were expanded using standard tissue culture techniques. Selected hybridomas were cryopreserved in fetal bovine serum (FBS) with 10% DMSO and stored in Liquid Nitrogen at -196°C to assure maintenance of viable clone cultures.

### Screening & Selection of Antibody Producing Hybridomas

Hybridoma cell lines were selected for production of Cln101 specific antibody by enzyme linked solid phase immunoassay (ELISA). Cln101 or Pro104 proteins were nonspecifically adsorbed to wells of 96 well polystyrene EIA plates (VWR). Fifty  $\mu$ L of Cln101 or Pro104 protein at 0.91 mg/mL in (DPBS) was incubated overnight at 4°C in wells of 96 well polystyrene EIA plates. Plates were washed twice with Tris buffered saline with 0.05% Tween 20, pH 7.4 (TBST). The plate wells were then emptied and nonspecific binding capacity was blocked by completely filling the assay wells with TBST/0.5% bovine serum albumin (TBST/BSA) and incubating for 30 minutes at room temperature (RT). The plate wells were then emptied, 50  $\mu$ L of hybridoma culture medium samples was added to the wells and incubated for 1 hour at RT. The wells were then washed 3 times with (TBST). One hundred  $\mu$ L of alkaline phosphatase conjugated goat anti-mouse IgG (Fc) (Pierce Chemical Co., Rockford, IL), diluted 1:5000 in TBST/BSA, was then added to each well and incubated for 1 hour at RT. The wells were then washed 3 times with TBST. One hundred  $\mu$ L of alkaline phosphatase substrate para-nitrophenylphosphate (pNPP) (Sigma) at 1mg/mL in 1 M Diethanolamine buffer pH 8.9 (Sigma) was then added to each well and incubated for 20 min. at RT. Bound alkaline phosphatase activity was indicated by the development of a visible yellow color. The enzymatic reaction was quantitated by measuring the solution's absorbance at 405 nm wavelength. Cultures producing the highest absorbance values are chosen for expansion and further evaluation.

### Western Blots

Protein extracts for western blot analysis were prepared in cell lysis buffer (1% NP-40, 10mM Sodium Phosphate pH 7.2, 150mM Sodium Chloride) from Cln101 expressing cell lines. Proteins were separated by electrophoresis on NuPAGE 4-12% Bis-Tris gels (Invitrogen Life Technologies, Carlsbad, CA) under denaturing conditions in Novex-XCell II Minicell gel apparatus (Invitrogen, Life Tech) and subsequently transferred to PVDF membranes using an XCell II Blot Module (Invitrogen Life Technologies). Following the transfer of proteins, the membranes were blocked in 1% blocking reagent (Roche Diagnostic Corp., Indianapolis, IN) and incubated overnight at 4°C with purified primary antibodies (Cln101 monoclonal antibodies: A46.1, A17.1, A9.1, A6.1 A26.1 and A38.1 ) and then with horseradish-peroxidase conjugated goat anti-mouse

IgG (Jackson ImmunoResearch Laboratories, Inc.) and finally visualized by chemiluminescence using an ECL advance western blotting detection kit (Amersham Biosciences, Piscataway, NJ).

The preferred antibodies were Anti Cln101 Mab A46.1, A17.1, A9.1, A6.1 A26.1  
5 and A38.1

ProteinChip SELDI Immunoassay for Cln101.

The ProteinChip SELDI mass spectrometry biosystem was obtained from Ciphergen Biosystems, Inc., 6611 Dumbarton Circle, Fremont, CA 94555. Preactivated surface ProteinChip arrays PS20 (Ciphergen Biosystems) have carbonyl diimidazole  
10 moieties that can react covalently with their amine groups. 0.4ug of purified MAB A16B recognizing the Cln101 was applied on each spot of a PS20 chip and incubated for 16 h at 4°C or 1 h at 37°C in a humidity chamber. An irrelevant MAB was used as a control. Residual active sites were then blocked by incubating the array in a 15-ml conical tube with 8 ml of 1 M ethanolamine, for 30 min, on a shaking platform. After three washes of 5  
15 min each with 0.05% Triton X-100 in PBS (pH 7.4) followed by 3 washes for 5 min with PBS (pH 7.4) in a 15-ml conical tube on a shaking platform, the chip was incubated for 4 h in a humidity chamber with 100 µl of normal and breast serum sample, 100ul of A549, HT29, PC-3 cell line medium at 100ng/ml using bioprocessor (Ciphergen Biosystems). The chip was washed as previously with 0.05% Triton X-100 in PBS (pH 7.4) and PBS  
20 (pH 7.4). Sinapinic acid was applied on each spot and mass spectrometry analysis was performed in a PBS-II mass reader (Ciphergen Biosystems). Spectra were collected using an average 80 nitrogen laser shots with a laser intensity of 280 and 290 and a detector sensitivity of 10. Spectrum analysis was performed using the ProteinChip software version 2.1(Ciphergen Biosystems). The result of ProteinChip SELDI Immunoassay for Cln101  
25 showed Mab 16B could capture a unique protein from HT29 medium about 16 kd, well other control antibodies could not. The size of captured protein is very close to the full length of Cln101 17 Kd, suggested that the captured protein in serum is Cln101. The capturing of Cln101 from serum was not successful.

Mab / Mab ELISA. A sequential sandwich ELISA assay was used to measure  
30 levels of Cln101 in serum. Assay consisted of monoclonal Ab capture, monoclonal Ab-biotin and Alk Phos detector. High binding polystyrene strip-wells were obtained from Corning Life Sciences (MA). The plates were coated overnight at 4oC with 0.5µg/well of

anti-Cln101 MAb. The coating solution was then aspirated off and blocked with 300µl/well of Superblock-TBS (Pierce Biotechnology, Illinois) for 1 hour at room temperature under shaking conditions. The blocking solution was then aspirated off and 20µl of Cln101 Standards diluted in 100% heat inactivated fetal bovine serum (Hyclone, UT) at concentrations of 6.25, 1.25, 0.5, 0.25, 0.1 and 0 ng/ml were then added to the wells. 20 µl of serum was also added to the other wells. 100 µl of Assay buffer containing 1% mouse serum, 10% FBS, and 1x TBS (Teknova, California) was then added to the 20 µl of samples and standards, and incubated at RT, shaking for 1 hour. The plate was washed four times with 360µl 1xTBS + 0.05% Tween-20 (Teknova, California).

10 Biotinylated Mab anti-Cln101 was diluted as 0.75ug/ml in 1x TBS pH 7.4 (Teknova, California) in Assay Buffer and 100 µl was added to each well and then incubated for 1 hour at room temperature while shaking. The plate was washed four times with 360 µl 1xTBS + 0.05% Tween-20 (Teknova, CA). 100µl of Alkaline Phosphatase conjugated Streptavidin, 1:2000 diluted in 1 x TBS pH 7.4 (Jackson ImmunoResearch Laboratories, PA) was added to each well and incubated for 30 minutes at RT while shaking. The plate was washed four times with 360µl 1xTBS + 0.05% Tween-20 (Teknova, California). The plate was developed using pNPP substrate in 1x DEA buffer (Pierce Biotechnology, Illinois) for 20 minutes at RT while shaking. The reaction was stopped using 100µl/well 1N NaOH, and read at 405nm using a Spectramax 190 plate reader (Molecular Devices, CA).

20 CA).

#### **Example 2: Monoclonal Sandwich ELISA Detection of Cln101**

High binding polystyrene plates (Corning Life Sciences (MA)) were coated overnight at 4°C with 0.8 µg/well of anti-Cln101 MAb. The coating solution was aspirated off and free binding sites were blocked with 300µl/well Superblock-TBS (Pierce Biotechnology, Illinois) plus 100% calf serum for 1 hour at room temperature (RT). After washing 4x with TBS+0.1%Tween20, 50µl of Assay Buffer (TBS, 1% BSA, 1% mouse Serum, 1% Calf Serum, 0.1% Tween20) was added to each well and then 50µl of antigen was added for 90 minutes incubation. For the checkerboard experiment, each pair was tested on 50 ng/ml and 0 ng/ml of recombinant Cln101. For each sandwich ELISA, standards of 10, 2.5, 0.5, 0.25, 0.1 and 0 ng/ml Cln101 were run in parallel with the test

25

30

samples. Standards and test samples were diluted in Assay Buffer. For the detection, 100  $\mu$ l of biotinylated MAb (1  $\mu$ g/ml) were added to each well and incubated for 1 hour at room temperature, while shaking. After washing, 100 $\mu$ l of horseradish peroxidase conjugated streptavidin (1mg/ml, Jackson ImmunoResearch Laboratories, PA) at a  
5 1:20,000 dilution was added to each well and incubated for 30 minutes at RT while shaking. After washing, the plate was then developed using DAKO TMB Plus substrate (DAKO, Denmark) for 30 minutes at RT. The reaction was stopped using 100  $\mu$ l/well 1N HCL, and the plates were read at 450nm using a Spectramax 190 plate reader (Molecular Devices, CA).

- 10 The results of the checkerboard ELISA for the anti-Cln101 A-series MAbs using bacterial recombinant Cln101 are shown in the table below.

### Identification of anti-Clon1 Antibody A-series Pairs

[illegible]

- 93 -

The results of the checkerboard ELISA for the anti-Cln101 C-series MABs using mammalian recombinant Cln101 are shown in the table below.

Identification of anti-Cln101 Antibody C-series Pairs

detecting Ab	A46	A9	C3	C6	C12	C17	C18	C25	C36	C43	C47	control
coating Ab												
A46	2	52	46	5	33	12	52	47	53	52	43	1
A9	43	1	1	44	41	49	3	46	3	8	3	1
C3	46	1	1	50	45	50	9	50	9	48	8	1
C6	3	54	45	2	3	4	49	1	52	1	44	1
C12	5	2	12	2	1	2	9	1	17	1	11	1
C17	23	37	20	1	1	6	44	1	33	1	43	1
C18	47	1	2	44	51	45	16	44	16	40	12	1
C25	49	45	44	1	1	2	45	1	48	1	43	1
C36	43	1	2	37	45	49	8	44	7	45	6	1
C43	45	1	50	2	1	3	44	2	48	1	42	1
C47	42	1	2	45	47	50	13	50	16	50	14	1

- 5 The results of the checkerboard ELISA for the anti-Cln101 A-series and C-series MABs using mammalian recombinant Cln101 are shown in the table below.

Identification of anti-Cln101 Antibody A and C-series Pairs

Detecting Ab	A6	A9	A10	A26	A38	A42	A46	C6	C17	C25	C36	control
Coating Ab												
A6	1	1	13	10	13	1	1	1	1	1	2	1
A9	1	1	18	1	1	1	44	21	20	22	2	1
A10	5	21	1	2	5	1	1	1	1	1	48	1
A26	3	1	2	1	1	2	4	4	4	3	1	1
A38	4	1	3	1	1	5	11	9	9	9	2	1
A42	1	1	1	2	2	1	6	1	1	1	8	1
A46	1	51	1	10	23	16	1	1	1	13	50	1
C6	1	19	1	6	17	1	1	1	1	1	48	1
C17	1	9	1	4	18	1	1	1	1	1	48	1
C25	1	5	1	2	8	1	6	1	1	1	51	1
C36	1	1	24	1	1	20	51	52	48	49	5	1
control	1	1	1	1	1	1	1	1	1	1	1	1

- For the checkerboard ELISA, all possible combination of antibodies, were tested
- 10 for efficiency as coating or detecting reagents. The pair A9.1 and A46.1 demonstrated an excellent signal/noise ratio and were further evaluated in sandwich ELISA assays to analyze the efficiency of detection of endogenous Cln101 in lysates from cancer cell lines and body fluids. Additional antibody pairs for detecting Cln101 include A10/C36, A46/C25, A46/C36, C6/A9, C6/C36, C36/A46, C36/C17, A9/C17 and A9/C6. Binding
- 15 results are graphically represented in Figure 1.

**Example 3: Cln101 Assays**Human serum samples

The human cancer serum samples in primary#1, primary #2 and secondary panel #1 were obtained from IMPATH-BCP, Inc.(Los Angeles, CA) and Diagnostic Support Service, Inc. (West Barnstable, MA). The human normal serum samples were obtained from ProMedDx, LLC. (Norton, MA). The human disease serum samples, primary panel #3 (cancer serum), colon, prostate, lung and breast extended panels (cancer and benign serum samples) and all the samples in legacy panel (cancer and normal serum samples) were obtained from Diagnostic Support Service, Inc., (West Barnstable, MA). Additional ovarian cancer samples were obtained from DIAGNOSTIC ONCOLOGY CRO, Inc. (DOCRO) (Seymour, CT). The ELISA assays were done in primary panel#1, primary panel#2, primary panel#3, benign panel, ProMedDx normal panel, bioavailability panel, colon and prostate extended panels and DOCRO ovarian panel . The primary#1 and #2 panel has 23 cancer serum samples for breast, Colon, Lung, Ovarian and prostate cancer each, plus 45 normal serums. The 25 cancer serum samples in each type covered different age (from 40 to 70) and mixed stage (stage1 to 4). All the normal serum samples were from ProMedDx, they covered a wide range of age (from 20 to 80) and both genders. The benign panels covered 16 disease, they are: Renal; Cystitis; Hypertension; BPH; Hepatic Toxicity; Prostatitis; Cirrhosis; Colon polyps; Diabetes; Ulcerative Colitis; Crohns; Nephrolithiasis; Polycystic; Glomerulonephritis; Pancreatitis; Diverticulitis. The bioavailability panel consists of 49 individuals with 6 to 9 multiple draws in one month of period time. The colon extended panel has 50 cancer serum samples and 200 benign serum samples (50 of each disease: Ulcerative Colitis; Crohns; Colon polyps; Diverticulitis). The prostate extended panel has 200 cancer serum samples and 100 benign serum samples (50 BPH; 50 Prostatitis). The DOCRO panel has 57 ovarian cancer serum samples and 24 Endometriosis serum samples.

Figures 2-8 show Cln101 in the all cancer panel, the prostate cancer panel, and the prostate cancer panel with benign diseases. Figure 9 shows PSA in the prostate cancer panel with benign diseases. Figure 10 shows Cln101 in ovarian cancer (DOCRO panel). For determination of PSA levels, the serum samples were tested with PSA ELISA kit from Biocheck Inc (Burlingame, CA) following the manufacturer's protocol.

**Example 4. ROC Analysis of Cln101 and PSA**

The ability of a test to discriminate diseased cases from normal cases is evaluated using Receiver Operating Characteristic (ROC) curve analysis (Metz, 1978; Zweig & Campbell, 1993). ROC curves can also be used to compare the diagnostic performance of two or more laboratory or diagnostic tests (Griner et al., 1981).

ROC curve is generated by plotting sensitivity against specificity for each value. From the plot, the area under the curve (AUC) can be determined. The value for the area under the ROC curve (AUC) can be interpreted as follows: an area of 0.84, for example, means that a randomly selected positive result has a test value larger than that for a randomly chosen negative result 84% of the time (Zweig & Campbell, 1993). When the variable under study can not distinguish between the two result groups, i.e. where there is no difference between the two distributions, the area will be equal to 0.5 (the ROC curve will coincide with the diagonal). When there is a perfect separation of the values of the two groups, i.e. there no overlapping of the distributions, the area under the ROC curve equals 1 (the ROC curve will reach the upper left corner of the plot).

The 95% confidence interval for the area can be used to test the hypothesis that the theoretical area is 0.5. If the confidence interval does not include the 0.5 value, then there is evidence that the laboratory test does have an ability to distinguish between the two groups (Hanley & McNeil, 1982; Zweig & Campbell, 1993).

ROC Analysis for Prostate Cancer (normal vs. cancer) analysis for individual markers for differentiation of normal males (n=121) from males with prostate cancer (n=138).

Statistic	Cln101	PSA
AUC (95% CI)	0.933 (0.895-0.960)	0.801 (0.747-0.848)
Cutoff for best combination of Sens/Spec.	0.306	3.7
Sens./Spec. at best cutoff	89%/92%	82%/67%
Sens. (@ 90% Spec.) (Cutoff)	90% (0.291)	34% (9.9)

Figure 11 shows the area under the curve for Cln101 and PSA (normal vs. cancer).

ROC Analysis for Prostate Cancer Synergistic effects (normal vs. cancer)  
Logistic regression results for differentiation of normal males (n=121) from males with prostate cancer (n=138) - Synergistic effects

Statistic	Cln101	Cln101 + PSA	PSA
ROC AUC	0.933	0.940	0.801
Wald p-value	<0.0001	Cln101: <0.0001 PSA: 0.002	<0.0001
Odds Ratio (OR)	1.2E-13	Cln101: 2.2E-12 PSA: 5.7E-8	8.3E-12
R2	0.5093	0.5523	0.1843
Sens. (@ 90% Spec.)	90%	85%	34%

ROC Analysis for Prostate Cancer (normals + benigns vs. cancer) Analysis for individual markers for differentiation of normal males and males with benign conditions (n=268) from males with prostate cancer (n=138)

Statistic	Cln101	PSA
AUC (95% CI)	0.741 (0.695-0.783)	0.762 (0.718-0.803)
Cutoff for best combination of Sens/Spec.	0.35	3.7
Sens./Spec. at best cutoff	87%/50%	82%/60%
Sens. (@ 90% Spec.) (Cutoff)	36% (1.08)	31% (10.8)

5

Figure 12 shows the area under the curve for Cln101 and PSA (normals + benigns vs. cancer).

10 ROC Analysis for Prostate Cancer Synergistic effects (normals + benigns vs. cancer) Logistic regression for differentiation of normal males and males with benign conditions (n=268) from males with prostate cancer (n=138) - Synergistic effects

Statistic	Cln101	Cln101 + PSA	PSA
ROC AUC	0.741	0.800	0.762
Wald p-value	<0.0001	Cln101: <0.0001 PSA: <0.0001	<0.0001
Odds Ratio (OR)	0.0011	Cln101: 0.004 PSA: 1.5E-8	1.4E-9
R2	0.1251	0.2374	0.1611
Sens. (@ 90% Spec.)	36%	44%	31%

#### Number of Serum Samples in PSA "Grey Zone"

Samples	PSA 2-4 ng/mL	PSA 4-10 ng/mL	PSA 2-10 ng/mL
Normal (n=121)	47	44	91
Prostate Cancer (n=138)	20	52	72
Prostate Benign (n=147)	40	40	80

15

ROC Analysis for Prostate Cancer Synergistic effects (normal vs. cancer, 4-10 ng/mL PSA) Logistic regression results for differentiation of normal males (n=44) from males with prostate cancer (n=52)

- 5 Synergistic effects in the diagnostic "grey zone" sub-population of patients with PSA 4.0-10.0 ng/ml

Statistic	Cln101	Cln101 + PSA	PSA
ROC AUC	0.937	0.950	0.526
Wald p-value	<0.0001	Cln101: <0.0001 PSA: 0.0700	0.6997
Odds Ratio (OR)	4.7E-13	Cln101: 2.6E-15 PSA: 11.8	0.736
R2	0.5252	0.5617	0.0014
Sens. (@ 90% Spec.)	88%	92%	6%

ROC Analysis for Prostate Cancer Synergistic effects (norm/ben vs. cancer, 4-10 ng/mL PSA) Logistic regression results for differentiation of normal males and males with benign conditions (n=84) from males with prostate cancer (n=52)

- 10 Synergistic effects in the diagnostic "grey zone" sub-population of patients with PSA 4.0-10.0 ng/ml

Statistic	Cln101	Cln101 + PSA	PSA
ROC AUC	0.657	0.657	0.522
Wald p-value	0.0041	Cln101: 0.0044 PSA: 0.9937	0.6634
Odds Ratio (OR)	0.041	Cln101: 0.041 PSA: 0.995	0.769
R2	0.0547	0.0547	0.0011
Sens. (@ 90% Spec.)	25%	25%	5%

ROC Analysis for Prostate Cancer Synergistic effects (normal vs. cancer, 2-10 ng/mL PSA) Logistic regression results for differentiation of normal males (n=91) from males

- 15 with prostate cancer (n=72)

Synergistic effects in the diagnostic "grey zone" sub-population of patients with PSA 2.0-10.0 ng/ml

Statistic	Cln101	Cln101 + PSA	PSA
ROC AUC	0.920	0.921	0.640
Wald p-value	<0.0001	Cln101: <0.0001 PSA: 0.3272	0.0105
Odds Ratio (OR)	5.6E-10	Cln101: 1.2E-9 PSA: 0.440	0.213
R2	0.4613	0.4667	0.0390
Sens. (@ 90% Spec.)	88%	81%	9%

ROC Analysis for Prostate Cancer Synergistic effects (norm/ben vs. cancer, 2-10 ng/mL PSA) Logistic regression for differentiation of normal males and males with benign conditions (n=171) from males with prostate cancer (n=72)

- 5 Synergistic effects in the diagnostic "grey zone" sub-population of patients with PSA 2.0-10.0 ng/ml

Statistic	Cln101	Cln101 + PSA	PSA
ROC AUC	0.694	0.714	0.627
Wald p-value	<0.0001	Cln101: <0.0001 PSA: 0.0123	0.0027
Odds Ratio (OR)	0.019	Cln101: 0.024 PSA: 0.292	0.245
R2	0.0838	0.1063	0.0328
Sens. (@ 90% Spec.)	26%	28%	9%

ROC Analysis for Prostate Cancer Synergistic effects (normal vs. cancer, 2-4 ng/mL PSA) Logistic regression results for differentiation of normal males (n=47) from males with prostate cancer (n=20)

- 10 Synergistic effects in the diagnostic "grey zone" sub-population of patients with PSA 2.0-4.0 ng/ml

Statistic	Cln101	Cln101 + PSA	PSA
ROC AUC	0.905	0.921	0.575
Wald p-value	0.0007	Cln101: 0.0010 PSA: 0.1778	0.4335
Odds Ratio (OR)	8.3E-7	Cln101: 1.4E-7 PSA: 0.14	0.47
R2	0.4137	0.4448	0.0095
Sens. (@ 90% Spec.)	62%	62%	24%

ROC Analysis for Prostate Cancer Synergistic effects (norm/ben vs. cancer, 2-4 ng/mL PSA) Logistic regression for differentiation of normal males and males with benign conditions (n=87) from males with prostate cancer (n=20)

15

Synergistic effects in the diagnostic "grey zone" sub-population of patients with PSA 2.0-4.0 ng/ml

Statistic	Cln101	Cln101 + PSA	PSA
ROC AUC	0.733	0.733	0.500
Wald p-value	0.0024	Cln101: 0.0023 PSA: 0.8370	0.9739
Odds Ratio (OR)	0.008	Cln101: 0.008 PSA: 1.21	1.03
R2	0.1368	0.1373	0.000
Sens. (@ 90% Spec.)	57%	52%	~2%

**Example 5. ROC Analysis of Cln101 and CA125**

The ability of a test to discriminate diseased cases from normal cases is evaluated using Receiver Operating Characteristic (ROC) curve analysis (Metz, 1978; Zweig & Campbell, 1993). ROC curves can also be used to compare the diagnostic performance of two or more laboratory or diagnostic tests (Griner et al., 1981).

ROC curve is generated by plotting sensitivity against specificity for each value. From the plot, the area under the curve (AUC) can be determined. The value for the area under the ROC curve (AUC) can be interpreted as follows: an area of 0.84, for example, means that a randomly selected positive result has a test value larger than that for a randomly chosen negative result 84% of the time (Zweig & Campbell, 1993). When the variable under study can not distinguish between the two result groups, i.e. where there is no difference between the two distributions, the area will be equal to 0.5 (the ROC curve will coincide with the diagonal). When there is a perfect separation of the values of the two groups, i.e. there no overlapping of the distributions, the area under the ROC curve equals 1 (the ROC curve will reach the upper left corner of the plot).

The 95% confidence interval for the area can be used to test the hypothesis that the theoretical area is 0.5. If the confidence interval does not include the 0.5 value, then there is evidence that the laboratory test does have an ability to distinguish between the two groups (Hanley & McNeil, 1982; Zweig & Campbell, 1993).

ROC Analysis for Ovarian Cancer (normal + benign disease vs. cancer) analysis for individual markers for differentiation of normal (n=31) or benign disease (endometriosis n=24) patients from patients with ovarian cancer (n=57).

Statistic	Cln101	CA125
ROC AUC	0.947	0.772
Sens. @ 90% Spec.	88%	67%
Spec. @ 90% Sens.	87%	4%

ROC Analysis for Ovarian Cancer synergistic effects (normal + benign disease vs. cancer) analysis for individual markers for differentiation of normal (n=31) or benign disease (endometriosis n=24) patients from patients with ovarian cancer (n=57).

Statistic	Cln101	CA125	CA125 + Cln101
ROC AUC	0.947	0.772	0.969
Sens. @ 90% Spec.	88%	67%	93%
Spec. @ 90% Sens.	87%	4%	95%

ROC Analysis for Stage 1 and 2 Ovarian Cancer (normal + benign disease vs. cancer) analysis for individual markers for differentiation of normal (n=31) or benign disease (endometriosis n=24) patients from patients with stage 1 and 2 ovarian cancer (n=28).

Statistic	Cln101	CA125
ROC AUC	0.921	0.696
Sens. @ 90% Spec.	79%	61%
Spec. @ 90% Sens.	75%	4%

5

ROC Analysis for Stage 1 and 2 Ovarian Cancer synergistic effects (normal + benign disease vs. cancer) analysis for individual markers for differentiation of normal (n=31) or benign disease (endometriosis n=24) patients from patients with stage 1 and 2 ovarian cancer (n=28).

Statistic	Cln101	CA125	CA125 + Cln101
ROC AUC	0.947	0.772	0.958
Sens. @ 90% Spec.	88%	67%	89%
Spec. @ 90% Sens.	87%	4%	85%

10

Cln101 showed efficacy in detecting ovarian cancer in samples where CA125 levels were not indicative of ovarian cancer. In addition to detecting ovarian cancer with CA125 levels below 30 U/ml, Cln101 is useful in detecting ovarian cancer where CA125 values are between 30 and 40 U/ml or between 30-35 U/ml.

15

ROC Analysis for CA125 negative (<30 U/mL) Ovarian Cancer (normal + benign disease vs. cancer) analysis for individual markers for differentiation of normal (n=31) or benign disease (endometriosis n=16) patients from patients with CA125 negative (<30 U/mL) Ovarian Cancer (n=19).

20

Statistic	Cln101
ROC AUC	0.940
Sens. @ 90% Spec.	84%
Spec. @ 90% Sens.	83%

## Results

ROC analysis results demonstrated Cln101 is an excellent marker for detecting ovarian cancer compared to known marker CA125. High Cln101 AUC scores indicate Cln101 is useful for detecting Stage 1 & 2 ovarian cancer alone or in combination with known marker CA125. Additionally, high Cln101 AUC scores indicate Cln101 is useful for detecting ovarian cancer in patients where known markers fail. Specifically, Cln101 detects ovarian cancer in patients with what is considered normal CA125 levels, CA125 <30 U/ml. Furthermore, multivariate (Cln101 + CA125) analysis may improve sensitivity and specificity for detecting ovarian cancer.

30

In summary, Cln101 is useful for detecting early stage ovarian cancer, ovarian cancer in general and discriminating between ovarian cancer and benign ovarian disease. Only 25% of all ovarian cancer is found in stage 1. If ovarian cancer is found in stage 1 therapy (e.g. surgery) is very effective and the 5-year survival rate is 90%.

## 5 Example 6: Deposits

### Deposit of Cell Lines and DNA

Hybridoma cell lines were deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, Virginia 20110-2209, U.S.A., and accorded accession numbers.

10 The following hybridoma cell lines were deposited with ATCC, Cln101.A9.1 and Cln101.A46.1. The names of the deposited hybridoma cell lines above may be shortened for convenience of reference. E.g. A01.1 corresponds to Cln101.A01.1. These hybridomas correspond to the clones (with their full names) deposited with the ATCC. The table below lists the hybridoma clone deposited with the ATCC, the accorded ATCC accession  
15 number, and the date of deposit.

#### ATCC deposits

Hybridoma	ATCC Accession No.	Deposit Date
Cln101.A9.1	PTA-5877	March 23, 2004
Cln101.A46.1	PTA-5876	March 23, 2004

These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent  
20 Procedure and the Regulations there under (Budapest Treaty). This assures maintenance of viable cultures for 30 years from the date of deposit. The organisms will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between diaDexus, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures to the public upon issuance of the pertinent U.S. patent or upon  
25 laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC §122 and the

Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).

The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable specimen of the same culture. Availability of the deposited strains are not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws. The making of these deposits is by no means an admission that deposits are required to enable the invention.

#### References:

Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. *J Clin Oncol.* 2003 Jan 15;21(2):383-91. Review.

Barry MJ Prostate-Specific-Antigen Testing for Early Diagnosis of Prostate Cancer *N Engl J Med* 344(18):1373-1377. Review.

Canto EI, Shariat SF, Slawin KM. Biochemical staging of prostate cancer.

*Urol Clin North Am.* 2003 May;30(2):263-77. Review.

Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer.

*Lancet.* 2003 Mar 29;361(9363):1122-8. Review.

Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific-antigen for detection of prostate cancer. *JAMA* 1995 273: 289-294.

Griner PF, Mayewski RJ, Mushlin AI, Greenland P (1981) Selection and interpretation of diagnostic tests and procedures. *Annals of Internal Medicine*, 94, 555-600.

Grossklau DJ, Smith JA, Shappell SB, Coffey CS, Chang SS, Cookson MS.

The free/total prostate-specific antigen ratio (% of PSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. *Urol Oncol.* 2002 Sep-Oct;7(5):195-8.

Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology*, 143, 29-36.

Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. *Radiology*, 148, 839-843.

- Hartupée JC, Zhang H, Bonaldo MF, Soares MB, Dieckgraefe BK. Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: Reg IV. *Biochim Biophys Acta* 2001 Apr 16;1518(3):287-93.
- 5 Jain S, Bhojwani AG, Mellon JK. Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. *Postgrad Med J.* 2002 Nov;78(925):646-50. Review.
- Kobayashi S, Akiyama T, Nata K, Abe M, Tajima M, Shervani NJ, Unno M, Matsuno S, Sasaki H, Takasawa S, Okamoto H. Identification of a receptor for reg (regenerating gene) protein, a pancreatic beta-cell regeneration factor. *J Biol Chem.* 2000 Apr 10 14;275(15):10723-6.
- Little B, Young M. How to use PSA to screen for prostate cancer. *Int J Clin Pract.* 2003 Jan-Feb;57(1):40-2.
- Metz CE (1978) Basic principles of ROC analysis. *Seminars in Nuclear Medicine*, 8, 283-298.
- 15 Okamoto H. The Reg gene family and Reg proteins: with special attention to the regeneration of pancreatic beta-cells. *J Hepatobiliary Pancreat Surg.* 1999;6(3):254-62.
- Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. *Clinical Chemistry*, 39, 561-577.

#### Web Sites:

- 20 cancer with the extension .gov/cancer\_information/cancer\_type/prostate/ of the world wide web

We Claim:

1. A method for assessing risk of prostate cancer in a patient which comprises measuring levels of both Cln101 and Prostate Specific Antigen (PSA) in the patient,  
5 analyzing a risk associated with the level of PSA and a risk associated with the level of Cln101, and using the combined risks to assess the risk of prostate cancer in the patient.
2. The method of claim 1 wherein the measuring of PSA and Cln101 levels are done simultaneously.
- 10 3. The method of claim 1 wherein the measuring of PSA and Cln101 are done sequentially.
4. The method of claim 1 wherein the respective levels of PSA and Cln101 are based  
15 on dividing a patient population dataset into borderline levels of PSA and elevated levels of Cln101 and a patient having both borderline PSA and high Cln101 levels is indicative of heightened risk of prostate cancer.
5. The method of claim 4 wherein the borderline levels of PSA are between about 2  
20 ng/mL and about 10 ng/mL.
6. The method of claim 4 wherein the borderline levels of PSA are between about 4 ng/mL and about 10 ng/mL.
- 25 7. The method of claim 4 wherein the borderline levels of PSA are between about 2 ng/mL and about 4 ng/mL.
8. A method for assessing risk of ovarian cancer in a patient which comprises measuring levels of Cln101 in the patient to assess the risk of ovarian cancer in the patient.

9. A method for assessing risk of ovarian cancer in a patient which comprises measuring levels of both Cln101 and CA125 in the patient, analyzing a risk associated with the level of CA125 and a risk associated with the level of Cln101, and using the combined risks to assess the risk of ovarian cancer in the patient.

—5—

10. The method of claim 9 wherein the measuring of CA125 and Cln101 levels are done simultaneously.

11. The method of claim 9 wherein the measuring of CA125 and Cln101 are done sequentially.

12. The method of claim 9 wherein the ovarian cancer is stage 1 or stage 2 ovarian cancer.

13. The method of claim 9 wherein the respective levels of CA125 and Cln101 are based on dividing a patient population dataset into CA125 levels not indicative of cancer and elevated levels of Cln101 and a patient having both CA125 levels indicative of cancer and high Cln101 levels is indicative of heightened risk of ovarian cancer.

14. The method of claim 13 wherein the CA125 levels not indicative of cancer are below about 30 U/ml.

15. The method of claim 13 wherein the CA125 levels not indicative of cancer are between about 30 U/ml and about 40 U/ml.

16. The method of claim 13 wherein the CA125 levels not indicative of cancer are between about 30 U/ml and about 35 U/ml.

17. A method for treating a subject with heightened risk of a prostate cancer, comprising: selecting a subject who has borderline levels of Prostate Specific Antigen

(PSA) and elevated levels of Cln101 and treating the subject with a therapy selected from the group consisting of surgery, radiation therapy, hormone therapy immunotherapy or chemotherapy so as to alleviate the heightened risk of prostate cancer in the subject.

- 5 18. A method for treating a subject with heightened risk of a ovarian cancer, comprising: selecting a subject who has elevated levels of Cln101 and treating the subject with a therapy selected from the group consisting of surgery, radiation therapy, hormone therapy, immunotherapy or chemotherapy so as to alleviate the heightened risk of ovarian cancer in the subject.

10

19. A method for treating a subject with heightened risk of a ovarian cancer, comprising: selecting a subject who has levels of CA125 not indicative of cancer and elevated levels of Cln101 and treating the subject with a therapy selected from the group consisting of surgery, radiation therapy, hormone therapy, immunotherapy or  
15 chemotherapy so as to alleviate the heightened risk of ovarian cancer in the subject.

20

20. A kit for diagnosing a patient's susceptibility to prostate cancer comprising both a suitable assay for measuring Cln101 levels and a suitable assay for measuring Prostate Specific Antigen (PSA) levels wherein the levels of both PSA and Cln101 are determined.

21. A kit for diagnosing a patient's susceptibility to ovarian cancer comprising a suitable assay for measuring Cln101 levels wherein the levels of Cln101 are determined.

22. A kit for diagnosing a patient's susceptibility to ovarian cancer comprising both a  
25 suitable assay for measuring Cln101 levels and a suitable assay for measuring CA125 levels wherein the levels of both CA125 and Cln101 are determined.

23. The kit of claim 20, 21 or 22 further comprising antibodies which bind the same epitopes as those produced by a hybridoma selected from the group consisting of ATCC  
30 accession number PTA-5877 and PTA-5876.

24. An isolated Cln101 antibody that binds to mammalian Cln101 in vivo or in vitro.
25. The antibody of claim 24 which internalizes upon binding to Cln101 on a  
5 mammalian cell in vivo.
26. The antibody of claim 24 or claim 25 which is a monoclonal antibody.
27. The antibody of claim 24 or claim 25 which is an antibody fragment.  
10
28. The antibody of claim 24 or claim 25 which is a chimeric or a humanized antibody.
29. The antibody of claim 26 which is produced by a hybridoma selected from the  
15 group consisting of American Type Culture Collection accession number PTA-5877 and PTA-5876.
30. The antibody of claim 26, wherein the antibody competes for binding to the  
20 same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma selected from the group consisting of ATCC accession number PTA-5877 and PTA-5876.
31. The antibody of claim 26 which is conjugated to a growth inhibitory agent.
32. The antibody of claim 26 which is conjugated to a cytotoxic agent.  
25
33. The antibody of claim 32 wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.
34. The antibody of claim 33 wherein the cytotoxic agent is a toxin.  
30
35. The antibody of claim 34, wherein the toxin is selected from the group consisting of ricin, saponin, maytansinoid and calicheamicin.

36. The antibody of claim 35, wherein the toxin is a maytansinoid.

37. The antibody of claim 26, wherein the mammalian Cln101 is produced by a  
5 cancer cell.

38. An anti-Cln101 monoclonal antibody that selectively binds a Cln101-  
expressing cell.

10 39. An anti-Cln101 monoclonal antibody that inhibits the growth of Cln101-  
expressing cancer cells in vivo.

40. The antibody of claim 39 which is a humanized or human antibody.

15 41. The antibody of claim 40 which is produced in bacteria.

42. The antibody of claim 38, which is a humanized form of an anti-Cln101  
antibody produced by a hybridoma selected from the group consisting of ATCC accession  
number PTA-5877 and PTA-5876.

20

43. The antibody of claim 39, wherein the cancer cells are from a cancer selected  
from the group consisting of prostate and ovarian cancer.

44. The antibody of claim 43, wherein the cancer is prostate or ovarian cancer.

25

45. A cell that produces the antibody of claim 26.

46. The cell of claim 45, wherein the cell is selected from the group consisting of  
hybridoma cells deposited under American Type Culture Collection accession number  
30 PTA-5877 and PTA-5876.

47. A method of producing the antibody of claim 26 comprising culturing an appropriate cell and recovering the antibody from the cell culture.
48. A composition comprising the antibody of claim 26 or claim 38, and a carrier.
- 5 49. The composition of claim 48, wherein the antibody is conjugated to a cytotoxic agent.
50. The composition of claim 49, wherein the cytotoxic agent is a maytansinoid.
- 10 51. The composition of claim 48, wherein the antibody is a human or humanized antibody and the carrier is a pharmaceutical carrier.
52. The composition of claim 51, wherein the humanized antibody is a humanized
- 15 form of an anti-Cln101 antibody produced by a hybridoma selected from the group consisting of ATCC accession number PTA-5877 and PTA-5876.
53. A method of killing a Cln101-expressing cancer cell, comprising contacting the cancer cell with the antibody of claim 24 or claim 25, thereby killing the cancer cell.
- 20 54. The method of claim 53, wherein the cancer cell is selected from the group consisting of prostate and ovarian cancer cells.
55. The method of claim 54, wherein the cancer cell is a prostate or ovarian cancer
- 25 cell.
56. The method of claim 55, wherein the ovarian cancer is ovarian serous adenocarcinoma.
- 30 57. The method of claim 54, wherein the cancer cell is from metastatic prostate or ovarian cancer.

58. The method of claim 53, wherein the antibody is an antibody fragment.

59. The method of claim 53 wherein the antibody is a humanized antibody.

5 60. The method of claim 53, wherein the antibody is conjugated to a cytotoxic agent.

61. The method of claim 60, wherein the cytotoxic agent is a toxin selected from the group consisting of maytansinoid, ricin, saporin and calicheamicin.

10

62. The method of claim 53, wherein the antibody is a humanized form of the antibody produced by a hybridoma selected from the group consisting of ATCC accession number PTA-5877 and PTA-5876.

15 63. The method of claim 60, wherein the cytotoxic agent is a radioactive isotope.

64. A method of alleviating a Cln101-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the antibody of claim 38 to the mammal.

20

65. The method of claim 65, wherein the cancer is selected from the group consisting of prostate and ovarian cancer.

25 66. The method of claim 65 wherein the ovarian cancer is ovarian serous adenocarcinoma cancer.

67. The method of claim 64, wherein the antibody is a humanized antibody.

30 68. The method of claim 64, wherein the antibody is conjugated to a cytotoxic agent.

69. The method of claim 63, wherein the cytotoxic agent is a maytansinoid.

70. The method of claim 69, wherein the antibody is administered in conjunction with at least one chemotherapeutic agent.

5 71. The method of claim 70 wherein the chemotherapeutic agent is paclitaxel or derivatives thereof.

72. An article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an antibody of claim 26.

10

73. The article of manufacture of claim 72 further comprising a package insert indicating that the composition can be used to treat prostate or ovarian cancer.

74. A method for determining if cells in a sample express Cln101 comprising  
15 (a.) contacting a sample of cells with an Cln101 antibody of claim 26 under conditions suitable for specific binding of the Cln101 antibody to Cln101 and  
(b.) determining the level of binding of the antibody to cells in the sample, or the level of Cln101 antibody internalization by cells in said  
20 sample,  
wherein Cln101 antibody binding to cells in the sample or internalization of the Cln101 antibody by cells in the sample indicate cells in the sample express Cln101.

75. The method of claim 74 wherein said sample of cells are contacted with an  
25 antibody produced by a hybridoma selected from the group of consisting of ATCC accession number PTA-5877 and PTA-5876.

76. The method of claim 74 wherein said sample of cells is from a subject who has a cancer, is suspected of having a cancer or who may have a predisposition for developing  
30 cancer.

77. The method of claim 76 wherein the cancer is a prostate or ovarian cancer.

78. The method of claim 74 wherein said antibody is a labeled antibody.

79. A method for detecting Cln101 overexpression in a test cell sample,

5 comprising:

(a.) combining a test cell sample with an Cln101 antibody of claim 26 under conditions suitable for specific binding of Cln101 to Cln101 expressed by cells in said test sample

(b.) determining the level of binding of the Cln101 antibody to the cells in the test sample,

10 (c.) comparing the level of Cln101 antibody bound to the cells in step (b) to the level of Cln101 antibody binding to cells in a control cell sample,

wherein an increase in the binding of the Cln101 antibody in the test cell sample as compared to the control is indicative of Cln101 overexpression by cells in the test cell sample.

15

80. The method of claim 79 wherein the test cell sample is a cancer cell sample.

81. The method of claim 80 wherein the cancer cell sample is of a prostate or ovarian cancer.

20

82. The method of claim 81 wherein the ovarian or prostate cancer is ovarian serous adenocarcinoma or metastatic cancer.

25 83. The method of claim 80 wherein the control is a sample of adjacent normal tissue.

84. A method for detecting Cln101 overexpression in a subject in need thereof comprising,

30 (a.) combining a bodily fluid sample of a subject with an Cln101 antibody of claim 26 under conditions suitable for specific binding of the Cln101 antibody to Cln101 in said bodily fluid sample

- (b.) determining the level of Cln101 in the bodily fluid sample,
- (c.) comparing the level of Cln101 determined in step b to the level of Cln101 in a control,

5 wherein an increase in the level of Cln101 in the bodily fluid sample from the subject as compared to the control is indicative of Cln101 overexpression in the subject.

85. The method of claim 84 wherein the subject has cancer.

86. The method of claim 85 wherein the subject has prostate or ovarian cancer.  
10

87. The method of claim 86 wherein the ovarian or prostate cancer is ovarian serous adenocarcinoma or metastatic cancer.

88. The method of claim 84 wherein the control is a bodily fluid sample from a  
15 subject without a cancer overexpressing Cln101.

89. A screening method for antibodies that bind to an epitope which is bound by an antibody of claim 26 comprising,


- (a.) combining an Cln101-containing sample with a test antibody  
20 and an antibody of claim 26 to form a mixture ,
- (b.) determining the level of Cln101 antibody bound to Cln101 in the mixture and
- (c.) comparing the level of Cln101 antibody bound in the mixture of step (a) to a control mixture,

25 wherein the level of Cln101 antibody binding to Cln101 in the mixture as compared to the control is indicative of the test antibody's binding to an epitope that is bound by the anti-Cln101 antibody of claim 26.


90. The screening method of claim 89 wherein the level of Cln101 antibody bound  
30 to Cln101 is determined by ELISA.

91. The screening method of claim 89 wherein the control is a mixture of Cln101, Cln101 antibody of claim 26 and an antibody known to bind the epitope bound by the Cln101 antibody of claim 26.
- 5 92. The screening method of claim 89 wherein the anti-Cln101 antibody is labeled.
93. The screening method of claim 92 wherein the Cln101 is bound to a solid support.
- 10 94. The screening method of claim 93 wherein the solid support is a sepharose bead.


**Figure 1. Anti-Cln101 MAb Epitope Map**




**Figure 2. Detection of Cln101 in Normal and Cancer Serum Samples (primary panel)**




**Figure 3. Detection of Cln101 in Normal and Cancer Serum Samples (primary panel), Expanded Scale**




**Figure 4. Detection of Cln101 in Normal and Cancer Serum Samples (multiple panels)**




**Figure 5. Detection of Cln101 in Normal and Cancer Serum Samples (multiple panels), Expanded Scale**



**Figure 6. Detection of Cln101 in Normal and Cancer Serum Samples (master panel)**



**Figure 7. Detection of Cln101 in Normal and Cancer Serum Samples (master panel), Expanded Scale**



**Figure 8. Detection of Cln101 in Normal, Prostate Cancer and Prostate Benign Serum Samples**






Figure 9. Detection of PSA in Normal, Prostate Cancer and Prostate Benign Serum Samples




**Figure 10. Detection of Cln101 in Normal, Ovarian Cancer and Ovarian Benign Serum Samples**




X Labels	ProMdx normal	Ovarian Cancer	Endometriosis	dDx normal
Number of values	31	57	24	13
Minimum	0.0070	0.0270	0.0070	0.0030
25% Percentile	0.0210	0.1470	0.0155	0.0070
Median	0.0370	0.2680	0.0270	0.0110
75% Percentile	0.0610	0.3860	0.0370	0.0260
Maximum	0.6760	1.689	0.1710	0.0380

**Figure 11. ROC Curves for CLN101 and PSA in Prostate Cancer vs. Normal Serum Samples**



**Figure 12. ROC Curves for CLN101 and PSA in Prostate Cancer and Benign Disease vs. Normal Serum Samples**



**AUC = 0.741**

**AUC = 0.762**

IAPI6 Rec'd PCT/PTO 29 NOV 2005

## SEQUENCE LISTING

<110> diaDexus, Inc.  
Duan, Xiaozhu  
Kim, Nam  
Wolfert, Robert

<120> Cln101 Antibody Compositions and Methods of Use Alone and in  
Combination with Prostate Specific Antigen and Other Cancer Markers

<130> DEX-0489

<150> US 60/556,239

<151> 2004-05-25

<150> US 60/474,110

<151> 2003-05-29

<160> 2

<170> PatentIn version 3.1

<210> 1

<211> 158

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic

<400> 1

Met Ala Ser Arg Ser Met Arg Leu Leu Leu Leu Ser Cys Leu Ala  
1 5 10 15

Lys Thr Gly Val Leu Gly Asp Ile Ile Met Arg Pro Ser Cys Ala Pro  
20 25 30

Gly Trp Phe Tyr His Lys Ser Asn Cys Tyr Gly Tyr Phe Arg Lys Leu  
35 40 45

Arg Asn Trp Ser Asp Ala Glu Leu Glu Cys Gln Ser Tyr Gly Asn Gly  
50 55 60

Ala His Leu Ala Ser Ile Leu Ser Leu Lys Glu Ala Ser Thr Ile Ala  
65 70 75 80

Glu Tyr Ile Ser Gly Tyr Gln Arg Ser Gln Pro Ile Trp Ile Gly Leu  
85 90 95

His Asp Pro Gln Lys Arg Gln Gln Trp Gln Trp Ile Asp Gly Ala Met  
100 105 110

Tyr Leu Tyr Arg Ser Trp Ser Gly Lys Ser Met Gly Gly Asn Lys His

2

115

120

125

Cys Ala Glu Met Ser Ser Asn Asn Asn Phe Leu Thr Trp Ser Ser Asn  
 130 135 140

Glu Cys Asn Lys Arg Gln His Phe Leu Cys Lys Tyr Arg Pro  
 145 150 155

<210> 2  
 <211> 171  
 <212> PRT  
 <213> Artificial sequence

<220>  
 <223> Synthetic

<400> 2

Met Leu Gln Asn Ser Ala Val Leu Leu Val Leu Val Ile Ser Ala Ser  
 1 5 10 15

Ala Thr His Glu Ala Glu Gln Asp Ile Ile Met Arg Pro Ser Cys Ala  
 20 25 30

Pro Gly Trp Phe Tyr His Lys Ser Asn Cys Tyr Gly Tyr Phe Arg Lys  
 35 40 45

Leu Arg Asn Trp Ser Asp Ala Glu Leu Glu Cys Gln Ser Tyr Gly Asn  
 50 55 60

Gly Ala His Leu Ala Ser Ile Leu Ser Leu Lys Glu Ala Ser Thr Ile  
 65 70 75 80

Ala Glu Tyr Ile Ser Gly Tyr Gln Arg Ser Gln Pro Ile Trp Ile Gly  
 85 90 95

Leu His Asp Pro Gln Lys Arg Gln Gln Trp Gln Trp Ile Asp Gly Ala  
 100 105 110

Met Tyr Leu Tyr Arg Ser Trp Ser Gly Lys Ser Met Gly Gly Asn Lys  
 115 120 125

His Cys Ala Glu Met Ser Ser Asn Asn Asn Phe Leu Thr Trp Ser Ser  
 130 135 140

Asn Glu Cys Asn Lys Arg Gln His Phe Leu Cys Lys Tyr Arg Pro Ala  
 145 150 155 160

Ser His His His His His His His His His His  
165 170